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ABSTRACT 
Context & Rationale:  Individuals with similar CD4 cell counts and RNA levels can 
vary considerably with regards to clinical progression. This variation is likely the result 
of a complex interplay between viral, host and environmental factors. This study aimed to 
characterize and identify predictors associated with disease progression to AIDS or death 
in Saskatoon, Saskatchewan.   
 
Methods: This is a retrospective cohort study of 343 seroprevalent HIV positive 
patients diagnosed from Jan 2005 to Dec 2010. Of these, 73 had an estimated 
seroconversion date. Data was extracted from medical charts at two clinics specialized in 
HIV/AIDS care. Disease progression was measured as time from HIV diagnosis (or 
seroconversion) to immunological AIDS and death. The Cox hazard model was used. 
 
Results: The 3-year and 5-year immunological AIDS free probability was 53% and 
33%, respectively. The 3-year and 5-year survival probability was 89% and 77%, 
respectively. Among the seroconversion cohort, the 3-year immunological AIDS free 
probability was 76%. 
 
Due to multicollinearity, separate models were built for IDU, hepatitis C and ethnicity. A 
history of IDU (HR, 3.0; 95%CI, 1.2-7.1), hepatitis C coinfection (HR, 2.9; 95%CI, 1.2-
6.9), baseline CD4 counts (HR, 0.95; 95%CI, 0.92-0.98, per ever 10 unit increase), ever 
on ART, and year of diagnosis were significant predictors of progression to 
immunological AIDS among the seroprevalent cohort. Age at diagnosis, sex and ethnicity 
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were not.  
 
For survival, only treatment use was a significant predictor (HR, 0.34; 95%CI, 0.1-0.8). 
Hepatitis C coinfection was marginally significant (p=0.067), while a history of IDU, 
ethnicity, gender, age at diagnosis, and year of diagnosis were not.  
 
Among the seroconversion cohort, no predictors of progression to immunological AIDS 
were identified. Ethnicity, hepatitis C coinfection and history of IDU could not be 
assessed. 
 
Conclusion: Our study found that IDU, HCV coinfections, baseline CD4 counts, and 
ART use were significant predictors of disease progression.  This highlights the need for 
increased testing and early detection and for targeted interventions for these particularly 
vulnerable populations to slow disease progression. 
 
! "#!
 
ACKNOWLEDGMENT 
 
It is wonderful to thank the many people who assisted with this thesis and made the 
journey most enjoyable and educational. First and foremost I wish to thank God. All is 
and has been possible through him. 
I am very grateful to my co-supervisors, Dr. Lim and Dr. Skinner, who provided 
valuable guidance and inspiration. Throughout my thesis, they provided encouragement, 
sound advice and good teaching. I would also like to extend my gratitude to my 
committee member, Dr. Janzen, and my two committee chairs, Dr. Abonyi and Dr. 
Reeder. Not to be missed, I would like to thank Germain Bukassa Kazadi for his 
wonderful guidance and his assistance in bringing research to an applied setting. 
I would also like to thank the many people who assisted with the data collection, 
including the friendly and helpful staff at the Positive Living Program and the Westside 
Community Clinic. A special thanks to Kali Gartner who collected the study data from 
the Westside Community Clinic. I am also very indebted to my wonderful classmates 
who made these two years so enjoyable.  
    Finally, I wish to thank my family for providing a loving and supporting environment. 
In particular, a big thank-you to my husband who never seizes to encourage me and 
support me in all my hearts desires. I dedicate this work to him.  
! #!
TABLE OF CONTENTS 
PERMISSION TO USE i 
ABSTRACT ii 
ACKNOWLEGDMENT iv 
LIST OF FIGURES viii  
LIST OF TABLES ix 
LIST OF APPENDICES xi 
ABBREVIATIONS xii 
1. Introduction 1 
1.1. Rationale of the study 1 
1.2. Purpose of the study 2 
1.3. Research objectives 3 
2. Literature Review 4 
2.1 HIV/AIDS 4 
2.2. HIV/AIDS Epidemiology 5 
2.2.1. Canada 5 
2.2.2. Saskatchewan 7 
2.2.3. Saskatoon 11 
2.3. Disease progression 12 
2.3.1. Measures of disease progression 17 
2.4. Potential prognostic factors influencing disease progression 20 
2.4.1. Demographics 20 
2.4.2.  Behavioural factors 31 
2.4.3. Clinical factors 37 
3. Methodology 40 
! #"!
3.1. Theoretical perspective & conceptual framework 40 
3.2. Study design 45 
3.3. Setting and population 45 
3.4. Operational and ethics approvals 46 
3.5. Data collection 46 
3.6. Inclusion/exclusion criteria 51 
3.7. Variable selection 53 
3.8. Dependent variables 56 
3.9. Statistical analysis 56 
4. Results 60 
4.1. Data manipulations 60 
4.2. Study population characteristics 60 
4.2.1. Differences by gender 64 
4.2.2. Differences by ethnicity 67 
4.2.3. Differences by history of IDU 70 
4.2.4. Differences by HCV coinfection 71 
4.3. Primary outcomes 74 
4.4. Survival analysis 76 
4.4.1. Time to CD4 count <200cells/µl 76 
4.4.1.1. Univariable analysis for immunological AIDS 79 
4.4.1.2. Multivariable analysis for immunological AIDS 81 
4.4.1.3. Multivariate analysis with baseline CD4 counts 83 
4.4.2. Time to death 85 
4.4.2.1. Univariable analysis for survival 87 
4.4.2.2. Multivariable analysis for survival 88 
! #""!
4.5. Subgroup analysis (Seroconversion Cohort)  90 
4.5.1. Study population characteristics 90 
4.5.2. Primary outcomes 93 
4.5.3. Survival analysis 94 
4.6. Summary of survival analysis 97 
5. Discussion 97 
5.1. Summary of findings 97 
5.2. Comparison of findings 98 
5.3. Study limitations 103 
5.4. Study strengths 105 
5.5. Study implications 106 
5.6. Future research directions 108 
5.6. Summary 109 
6. REFERENCES 110 
7. APPENDICES 133 
! #"""!
LIST OF FIGURES 
 
Figure 1.1 Annual incidence rates for select provinces in Canada, from 2000       p.8 
to 2008  
Figure 1.2 CD4 cell counts and viral load changes during progression of disease     p.14 
Figure 1.3 HIV-RNA levels and CD4 counts at three rates of disease progression       p.16 
Figure 3.1 HIV disease progression conceptual model         p.43 
Figure 3.2 Summary of inclusion process into study dataset        p.52 
Figure 4.1 Percentage of overlap between Aboriginal ethnicity, history of IDU,         p.74 
and HCV coinfection 
Figure 4.2 Summary of type of analysis and frequency of outcome of interest     p.76 
Figure 4.3 Survival function of immunological AIDS from HIV diagnosis       p.77 
Figure 4.4 Survival functions of immunological AIDS, stratified by treatment            p.78 
status, record of incarceration, and diagnosis year 
Figure 4.5 Survival curve for all-cause mortality from HIV diagnosis                          p.86 
Figure 4.6 Illustration of overlap between Aboriginal ethnicity, history of IDU,         p.92 
and HCV coinfection for seroconversion cohort 
Figure 4.7 Survival curve for immunological AIDS from HIV infection      p.95 
 
! "$!
LIST OF TABLES 
 
Table 1. Independent variables available in the database     p.54 
Table 2. Independent variables used in data analysis      p.55 
Table 3. Study population characteristics       p.63 
Table 4. Study characteristics stratified by gender      p.69 
Table 5. Study characteristics stratified by ethnicity      p.71 
Table 6. Study characteristics stratified by IDU      p.72 
Table 7. Study characteristics stratified by hepatitis C antibody status   p.73 
Table 8. Pearson’s correlation of selected variables      p.80 
Table 9. Univariable Cox regression analysis for immunological AIDS   p.82 
progression 
Table 10. Multivariable Cox regression analysis for ethnicity    p.82 
Table 11. Multivariable Cox regression analysis for HCV coinfection   p.82 
Table 12. Multivariable Cox regression analysis for IDU      p.83 
Table 13. Adjusted multivariable model with baseline CD4 counts    p.84 
Table 14. Adjusted multivariable model with baseline CD4 counts   p.84 
Table 15. Adjusted multivariable model with baseline CD4 counts    p.85 
! $!
Table 16. Univariable cox regression analysis for all cause mortality   p.87 
Table 17. Multivariable Cox regression analysis for ethnicity    p.88 
Table 18. Multivariable Cox regression analysis for hepatitis C antibody status p.89 
Table 19. Multivariable Cox regression analysis for IDU     p.89 
Table 20. Study characteristics of seroconversion cohort     p.91 
Table 21. Summary of percentage without AIDS and survival of HIV positive  p.96 
patients  
!"#!
LIST OF APPENDICES!
 
Appendix 1. Definition of Terms         p.131 
Appendix 2. Medical Chart Forms         p.134 
Appendix 3. Exposure Category (Risk Factor) Hierarchy     p.141 !
! $""!
!
ABBREVIATIONS 
 
 
AIDS  Acquired immunodeficiency syndrome 
AI/AN  American Indians/Alaska Natives 
ART   Antiretroviral therapy 
CI   Confidence intervals 
FN   First Nations 
HAART  Highly active antiretroviral therapy 
HC   Heterosexual contact 
HCV   Hepatitis C virus 
HIV   Human immunodeficiency virus 
HR   Hazard ratio 
IDU   Intravenous drug users 
MSM  Men who have sex with men 
PHAC  Public Health Agency of Canada 
PLP   Positive Living Program 
SHR   Saskatoon Health Region 
SK   Saskatchewan 
STI   Sexually transmitted infection 
WCC  Westside Community Clinic 
!
 
1. Introduction
1.1. Rationale of the study
The rates of new cases of HIV among adults (≥ 15 years) in Saskatchewan (SK) have risen over 
the past 5 years from 3.3 to 20.8 per 100,000 population, the highest HIV incidence rate in 
Canada and almost twice the national average.1 Over 70% of new cases are intravenous drug 
users (IDU) and over 60 % of cases are of First Nation or Métis descent. Surveillance findings 
and clinicians report high levels of co-infection with hepatitis C. Most HIV notifications within 
Saskatchewan are from three urban centers, Saskatoon, Regina, and Prince Albert.2 
Saskatchewan clinicians report rapid deterioration of HIV cases to AIDS and have observed that 
at diagnosis a number of cases have both high viral loads and low CD4 counts, as stated by the 
HIV Surveillance officer for Saskatchewan (G. Bukassa Kazadi, oral communication, March 
2011). CD4 count is an important indicator of disease stage and prognosis for HIV positive 
individuals.3, 4 Patients with low CD4 counts have increased susceptibility to opportunistic 
infections, are more likely to acquire AIDS, and have an increased risk of mortality. Moreover, it 
has been shown that treatment response can be suboptimal in patients with low CD4 counts, 
compared to patients with higher counts.4, 5 
It is unclear whether this trend of low CD4 counts at diagnosis is the result of a late diagnosis or 
rapid disease progression. While late diagnosis is definitely a possibility, other studies are 
potentially pointing towards the latter option. Studies by one research team have suggested the 
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possibility of a more virulent virus than in later decades.6-8 A recent report on Saskatoon’s inner 
core population, provided support to these anecdotal claims by showing rapid progression in 
16% of its study population, a significantly higher proportion than the 5-10% typically observed.
9 The province of Manitoba has also noted a higher proportion of rapid progressors than typically  
observed. The mechanisms which drive HIV disease progression are complex and not well 
understood. 
1.2. Purpose of the study
The HIV spread has prompted the Saskatchewan HIV Strategy 2010-2014, supported by a fund 
of 2.5 million by the Saskatchewan Ministry of Health. Among other objectives, this strategy 
calls for a decrease in the number of HIV patients progressing rapidly to AIDS.10 In accordance 
with these goals, this study aimed to characterize and identify individual determinants of HIV 
disease progression.  
Identification of factors influencing disease progression is vital to effectively care for patients 
and to improve their survival and quality of life. The detection of clinical features and 
characteristics associated with a more rapid progression can help identify patients who may 
benefit from a closer and more frequent clinical follow-up. Moreover, this study will enable 
evidence-informed policy development and contribute to a more comprehensive understanding 
of disease progression in the Saskatchewan population. Furthermore, this study examines a 
unique and under-researched population, where HIV is a new emerging health concern.  
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1.3. Research objectives
The general research objectives of this study were as follows:
Objective 1. To characterize HIV disease progression for the study population
 1.1 To estimate the time to immunological AIDS
 1.2. To estimate the time to death
Objective 2. To identify risk factors associated with disease progression
2.1. To compared disease progression between HIV/Hepatitis C co-infected and HIV 
mono-infected patients
2.2. To compare disease progression between Aboriginal people and non-Aboriginal people
2.3. To compare disease progression between IDUs and non-IDUs
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2. Literature Review
This section provides a brief introduction of HIV and AIDS. The magnitude of the problem, 
including the epidemiology of HIV/AIDS at a global, national and local level, are also described. 
The section then explores HIV disease progression and the various definitions used to measure 
progression. Finally, an overview of potential proximate prognostic factors influencing disease 
progression are also presented. 
2.1 HIV/AIDS
The human immunodeficiency virus (HIV) is a retrovirus (lentivirus) that causes acquired 
immunodeficiency syndrome (AIDS), a condition in which the immune system begins to 
deteriorate, exposing infected individuals to life-threatening opportunistic infections. HIV is 
transmitted person to person by the transfer of bodily fluids, such as blood, semen, and vaginal 
fluid.  The major routes of transmission include unprotected sexual intercourse, contaminated 
needles, and mother to child transmission.11 
A cure or vaccine for HIV or AIDS does not currently exist. However, great strides have been 
made in treatment termed highly active antiretroviral therapy (HAART). HAART consists of 
cocktails of at least two to three different classes of antiretroviral therapies and effectively lowers 
the concentration of the virus in the body. In most developed countries, where these drugs are 
available, a large reduction in HIV-associated morbidity and mortality has occurred to the extent 
that HIV/AIDS is now considered a chronic condition.11    
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2.2. HIV/AIDS Epidemiology
The World Health Organization considers HIV infection a pandemic that has claimed the life of 
more than 25 million people worldwide. In December 2008, it was estimated that there were 33.4 
million people living with HIV globally, with 2.7 million new infections that year. In 2008, there 
were 2.0 million deaths.12 While the prevalence of HIV infected individuals continues to 
increase, due to the continued addition of new HIV cases and the decrease in deaths, the 
incidence of HIV is decreasing. The incidence rate peaked in the mid 1990s with roughly 3.5 
million new infections per year and has since decreased by 30% in 2008.12 In general, the global 
incidence of HIV has been stable in the decade of 2000-2009 (but with important regional 
differences in trends and modes of transmission).13
2.2.1. Canada
In Canada, HIV has caused over 13,500 deaths.1 Estimates in 2008 state that there are 65,000 
Canadians living with HIV, a 14% increase from 2005.14  While the number of Canadians living 
with HIV continues to rise, the incidence rate appears to be stable at around 2500 new cases per 
year since 2002.1  In 2008, however, the number of new cases did show a 7.0% increase from the 
previous year.1
 
The Surveillance Report released by the Public Health Agency of Canada (PHAC)1 revealed 
more details with regards to the national trends. In 2008, older age groups (40-49 years of age 
and 50+) represented an increased proportion of positive HIV test reports. Female cases, while 
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less prevalent than male cases since 1999, have also shown to be consistently rising. When 
stratified by age, only in the 15-19 age group were females more numerous than males (58.3% 
vs. 41.7%) in 2008, a trend noted since 1999. The most frequently reported exposure categories 
among adults in 2008 were MSM (45.1%), heterosexual contact (30.8%), and IDU (19.1%).  
Trends according to ethnicity comparing the 1998-2002 period with 2008, showed a decline in 
whites (from 61.3% to 44.6%), and an increase in Aboriginal persons (from 23.4% to 29.4%) and 
black Canadians (from 7.3% to 14.5%). The overall incidence rate among Aboriginal persons 
was 3.6 times higher compared to non-aboriginal persons in 2008.1
The number of AIDS diagnosis have consistently dropped since peaking in 1993 with 1829 cases 
to about 255 cases in 2008. Among adults, males continue to be more prevalent among AIDS 
cases, representing up to three quarters of the cases. According to exposure categories, MSM 
similarly accounts for the largest portion of AIDS cases (45.5%) followed by heterosexual 
contact (30.5) and IDU (19.0%), among adults in 2008. When stratified by sex and ethnicity, key 
differences emerged.  Among males, MSM accounted for a slightly higher percentage (56.1%) 
while IDU was slightly lower (9.2%).  For females, IDU accounted for the majority of AIDS 
cases (60.9%) with the remained accounted by heterosexual contact (39.1%).  Among Aboriginal 
adults, over 50% of AIDS diagnoses have been attributed to IDU from 1999 to 2008. MSM 
constitutes about 10% of AIDS diagnoses, while heterosexual contact accounted for about 30%.  
This is in comparison to Whites in which over 50% of AIDS diagnoses were attributed to MSM, 
followed by IDU (20%) and heterosexual exposure (19%).  Aboriginal persons accounted for 
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2.8% of all AIDS diagnosis from 1979 to 2008, the third highest percentage, following White 
(81.4%) and Blacks (9.3%).  
2.2.2. Saskatchewan
Unlike the national trend, since 2003, SK has seen a consistent rise in new HIV cases. The 
populations growing problem is not only concerning, but also quite unique when compared to 
national trends. This section discusses SK’s HIV epidemiology and provides a comparison to the 
national trends. In addition, it comments on the large problem of IDU and concludes with 
comments on SK’s HIV epidemic.
Epidemiological statistics show the emergence of HIV in the province of SK. Since 1984, when 
HIV became notifiable, there were 1198 HIV cases, of which 75% were identified in the years 
2000-2009.2 Compared to 2007, this province experienced a 40% increase in the number of new 
cases of HIV in 2008, and an additional 15% increase in 2009. 2 This new incidence rate has 
situated SK above the nation’s rate.1 Annual incidence rates for the provinces most affected by 
HIV are presented in Figure 1.1.
7
Figure 1.1. Annual incidence rates for select provinces in Canada, from 2000 to 2008
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From an epidemiological standpoint, SK’s growing HIV situation is quite unique. The 
demographics of this provinces HIV population differ greatly from the national trends.  SK has 
the lowest male to female ratio at 3:2, compared to the national ratio of 5:1 from 1985 to 2008.1 
Trends in gender have fluctuated within the last 10 years. Since 2007, male cases have surpassed 
female cases. When stratified by age, 2009 data shows female continued to more numerous in the 
lower age groups (15-29 years) while males were more numerous in the older age groups (>30 
years),2 as was the case in 2008.1 In 2008, the mean age of female cases was 30.8 years with a 
range from 15-53, while male cases had a mean age of 37.8 with a range from 16-77.1  
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Aboriginal people are over represented in SK’s HIV population comprising 79% of all new HIV 
cases in 2009, compared to the national rate of 29.4%.1 Since 2006, they annually represent over 
65% of new cases. This disparity is even more notable among females; eighty-nine percent of all 
female cases were Aboriginals in 2008 (70% for males).2
In terms of exposure categories, SK’s major route of transmission continues to be injection drug 
use. In the early 2000s, IDU exposure accounted for nearly half of all HIV cases annually in SK. 
This percentage has since risen to 75% in 2008,15 which is much higher than the national 
percentage of 18.9%.1 In SK, MSM and heterosexual contact continue to stay constant with only 
a slight increase from 2006 to 2008. In 2008, MSM accounted for less than 5% of new cases 
while heterosexual contact accounted for less than 3%.15 This trend contrasts with the nation’s 
major route of transmission, MSM (45%).1 Transmission via IDU has actually been decreasing in 
Canada.1 
AIDS diagnosis became a reportable disease in 1984. Since then, there have been 271 AIDS 
cases in SK, comprising of 215 males and 56 females. In 2009, there were 14 AIDS cases. With 
regards to mortality among AIDS cases, there have been 199 deaths since 1984. In 2009, six 
newly diagnosed AIDS cases died within the same year of their diagnosis.2
The major mode of transmission points to the significant problem of IDU in Saskatchewan. 
According to estimates in 2008, there were roughly 5,000 IDUs in the province, concentrated in 
the three largest cities; powdered cocaine and opiates, particularly morphine, identified as the 
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most commonly used injection drugs.16 These IDU are marginalized and impoverished 
populations, many suffering from abuse and neglect, lack of education and employment and 
racism.16 While HCV co-infections appeared to be common in the early 2000s, HIV appears to 
be a new concern for these individuals. The I-track, an enhanced surveillance assessment among 
IDUs, was carried out in seven cities across Canada, including Regina, SK in 2004.17 The study 
include 250 IDUs residing in Regina at the time of data collection. HIV tests found the 
prevalence among these IDUs to be 2.9%, roughly 10 times higher than that of the Canadian 
adult population (0.3%), but much lower than the average national rate of 14% among IDUs. 
However, the prevalence of HCV was found to be 63.7%, which closely resembled the 
prevalence of other cities. However, in 2007 HIV had risen to 9.0% (information from the I-track 
study, not yet published and obtained from the Needle Exchange Review Report16). In 2008, the 
Saskatoon Health Region (SHR) reported a prevalence of 15.0% among its active registered 
needle exchange clients.16
The rise in cases in SK is likely attributed to a continued spread of the virus and not other 
potentially competing causes (such as increased testing). However, it is important to note that 
beginning in 2005, the consistent rise in HIV cases caused changes in public health surveillance 
contact tracing.18 Initiated at the SHR, additional naming of ‘other individuals that you may feel 
are at-risk for HIV acquisition’ was included in contact tracing. This enhanced surveillance 
investigation method helped public health workers identify other individuals who may benefit 
from testing. This was later adopted by the Regina Qu’Appelle Health Region and assisted 
further identification of HIV positive individuals. While this protocol change may have 
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accounted for some of the increase in HIV cases in the years that followed, it is unlikely to 
account for all of it.  In 2005, 0.14% of all specimens tested positive.  This percentage had 
steadily increased to 0.37% in 2008, indicating a continued spread of HIV infections.15
2.2.3. Saskatoon
The Saskatoon Health Region (SHR) encompasses the city of Saskatoon along with numerous 
surrounding communities, rural municipalities and First Nations communities.  The region 
accounts for 5.25% of Saskatchewan’s geographic area and approximately 30% of the province’s 
population.19 Data specific to Saskatoon is not generally available, and thus data from the SHR 
will be discussed, unless otherwise stated.
Within SK, the SHR has been particularly burdened by the spread of HIV.  Since 2004, the rates 
of new HIV infections for the SHR have consistently been slightly higher than that of the 
provincial rate.19 However, in more recent years, this disparity has widened, with an incidence of  
31.3 per 100,000 in 2009 for SHR compared to 20.0 for the province.19 In total, the region 
accounted for ~48% of the province’s new cases in 2009.20 
HCV, hepatitis C virus, causing chronic liver disease, has also been increasing in the health 
region. The incidence rate increased from 63.3 per 100,000 in 1996 to 82.4 in 2008. This is in 
contrast to the national trend where HCV infections are decreasing.19
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Similar to provincial trends, IDU continues to be a major driver of HIV infections in SHR. It is 
estimated that there are roughly 2000 IDUs in Saskatoon.16 As mentioned previously, based on 
the database from the needle exchange site in Saskatoon, the prevalence of HIV among active 
registered needle exchange clients was 15.0% in 2008. In addition to addiction problems, these 
individuals are of great concern due to other reasons, including high mobility and unwillingness 
to seek care. Based on a survey administered in 2008 to IDUs in Saskatoon, over one third 
(37.7%) of participants reported spending three or more consecutive days in a rural community 
or reserve in the last six months.21 This was similar among those reporting a history of HIV 
(38.9%). The survey also found that 45.7% of participants did not go to health care centre even 
when they thought they should; the majority mentioned discrimination as a reason why they did 
not seek care. These are concerning findings given the self-reported prevalence of HIV and 
HCV among these survey participants was 23.8% and 79.5%, respectively. Transient behaviours, 
particularly travel to rural communities, is concerning as harm reduction services such as needle 
exchange programs are not available in many rural areas of SK and an average of 18.5 needles 
per person per day was reported among these study participants.21  
2.3. Disease progression
HIV disease progression is a continuum of progressive damage to the immune system from the 
time of infection to the manifestation of severe immunologic damage by opportunistic infections 
or low CD4+ T-lymphocyte that define AIDS.  CD4+ T-lymphocytes will be described below. 
Progression can be described to follow a rudimentary course that includes an acute infection, a 
clinically asymptomatic period, a symptomatic period and death. Generally, the time of infection 
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is unknown. Nevertheless, the acute infection is the initial HIV infection characterized by a 
period of flu-like symptoms. During this stage the body produces HIV antibodies and 
seroconverts to HIV-positive status. This stage is often referred to as seroconversion. Following 
seroconversion is the asymptomatic period, in which the virus is present in the body but does not 
produce significant symptoms. As the virus continues to replicate there is progressive damage to 
the immune system subsequently leading to clinical symptoms and opportunistic infections. A 
profound immune suppression is representative of a clinical diagnosis of AIDS. Without 
treatment, HIV infection will typically lead to death.22
However, considerable variability is seen in the natural history of HIV disease progression.23 
While the stages mentioned above tend to occur in sequence, it is possible to experience several 
stages simultaneously or to alternate among stages. To better understand the variability, two key 
biomarkers need to be discussed.
CD4+ T lymphocytes and viral load are considered important biomarkers of HIV disease 
progression. CD4+ T lymphocytes are cells of the immune system, which begin to deplete as the 
virus infects the body.  These cells are more simply termed CD4 cells and will be referred like so 
from here onwards. Viral load is a term referring to the HIV RNA concentration in the body.  As 
the virus replicates, the RNA concentration increases in the bodily fluids, including the blood.  
Both of these markers are measured through a blood sample and result in the count of CD4 cells 
per millimeter cubed and the number of viral copies per milliliter of blood.22 
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Given its direct relation to the immune system, CD4 cell counts are the primary indicator for 
prognostic information and a guide for antiretroviral therapy for HIV-positive individuals.24 
However, the combination of the viral RNA (i.e., viral load) and CD4 cell count more accurately 
predict the time to AIDS than the CD4 cell count alone. The CD4 cell count indicates the degree 
of immunosuppression, and a viral load correlates with more rapid progression.24  Figure 1.2 
illustrates how these two biomarkers highlight changes in disease progression. 
Figure 1.2. CD4 cell counts and viral load changes during progression of the disease
Source:  Originally published as Figure 1 in Pantaleo G, et al. New concepts in the immunopathogenesis of human 
immunodeficiency virus infection. New England Journal of Medicine, 1993;328(5)
As can be seen in Figure 1.2, there is an initial drop in CD4 cell during the acute infection, 
followed by a small rebound in the following year. Subsequently, CD4 counts progressively 
decline over time. The decline in CD4 cells varies for each individual. Similarly, the 
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concentration of the virus spikes during infection, followed by a slower incline in the following 
years. The subsequent increase in viral load will vary for each individual.
As mentioned, this pattern in progression varies considerably. Review of progression among the 
HIV population has lead to three main patterns in progression rates. The key differences are 
highlighted by the different trends in CD4 counts and viral load. These three patterns are 
illustrated in Figure 1.3. 
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Figure 1.3. HIV-RNA levels and CD4 counts at three rates of disease progression
Source: Langford et al. Predictors of disease progression in HIV infection: a review. AIDS Research and Therapy. 
2007;4(11).
Patients following the various rates have been termed typical progressors or intermediate 
progressors, long-term nonprogressors, and rapid progressors.22 Typical progressors represent 
roughly 50-70% of HIV infected individuals.  For the majority of the population, disease 
progresses over 8-10 years from infection to AIDS.   Long-term nonprogressors experience 
delayed progression as indicated by measures such as CD4 cell loss, viral load, and time to 
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death.  Long-term nonprogressors carry on without AIDS for 10 or more years, comprising about 
5% of the population. Rapid progressors, on the other hand, develop AIDS in 2-3 years from 
seroconversion and comprise 5-10% of all HIV infected individuals. These individuals have a 
rapid decline in CD4 cells and increase in viral load.22
 
2.3.1. Measures of disease progression
Various measures with differing endpoints have been used to define disease progression. No one 
definition is more prominent or important than the other; instead, each definition contributes to 
the overall understanding of disease progression.  Below is a brief description of the various 
measure used to define disease progression, what information each contributes, and their 
limitations.
Observed AIDS-free Interval
One commonly used measure is referred to as an observed AIDS-free interval, which measures 
time from HIV diagnosis to AIDS.  Its popularity is likely due to the availability of these two 
data points. Within this definition, AIDS diagnosis has be classified in one of two ways. Clinical 
AIDS refers to a diagnosis due to the development of an AIDS defining disease, as per the 
corresponding guidelines.  Immunological AIDS refers to the development of severe CD4 
lymphocytopenia (i.e. CD4 count < 200 cells/µL). Both clinical AIDS or immunological AIDS 
are representative definitions for advanced HIV disease.25 
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The observed AIDS-free interval provides important information about disease progression 
following diagnosis. However, an observed AIDS-free interval is shaped by the timing of HIV 
diagnosis and therefore does not allow a differentiation between late diagnosis and rapid 
progression.  Nevertheless, by controlling for CD4 counts at diagnosis, comparisons between 
groups can be performed.  Cohorts that deliver information from HIV diagnosis are referred to as 
seroprevalent cohorts.
HIV to Death
Mortality is an alternate endpoint used to define the progression of the disease.  Death can be 
specific to the diagnosis (i.e. HIV-related mortality) or non-specific (i.e. all cause mortality).  
Both provide important information about the causes of death specific to HIV positive 
populations, given this population increased susceptibility to other chronic conditions.  This 
measure of progression, time from HIV diagnosis to death, provides important information about 
survival following HIV diagnosis, valueable data for health care planning.  Nevertheless, 
measures relying on date of diagnosis as the starting point can not provide “true” data on disease 
progression.  
HIV seroconversion to AIDS and Death
A more accurate measure of disease progression defines time from HIV seroconversion to AIDS 
or death. These two measures provide data unbiased by the delay in diagnosis. Occasionally 
these measures are limited to data prior to treatment initiation, providing information on the 
natural course of HIV disease progression.  However, it is sometimes more informative to 
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include data following treatment. This latter measure provides information on the real 
progression of the disease within the context of the resources that are available, such as 
treatment.
Unlike HIV diagnosis, the date of seroconversion is generally unknown, and difficult to obtain.  
Occasionally, when an HIV test result is indeterminate, the specimen is further tested for a p24 
antigen, which is present in the blood only during the initial phase of HIV infection. This, along 
with recent prior negative HIV tests, are appropriate methods available for obtaining an 
estimated seroconversion date when dealing with retrospective data.26, 27
Overcoming the initial obstacle of determining the initial infection has its advantages. As 
mentioned previously, working with HIV seroconversion allows disease progression to be 
evaluated in its truest form and allows for equal comparisons.  This measure is not biased by 
delays in diagnosis.  A cohort containing this information is referred to as a seroincident (or 
seroconversion) cohort.
CD4 cell decline
The final measure that is commonly employed takes advantage of an important biomarker in 
disease progression, CD4 counts. While slightly variable during the initial phase of infection, 
CD4 counts slowly decrease through the chronic phase of infection. During this specific stage, 
CD4 counts have been shown to decrease in a linear association with time. When looking to 
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compare groups, this measure has a strong advantage. Unlike time-to-event analysis, which all 
the previous measures would generally require, this measure uses longitudinal analysis resulting 
in a difference of CD4 counts per specified time between the groups of interest. This difference 
is easy to understand and interpret. A time-to-event analysis, provides a hazard ratio (HR), which 
is less easy to understand. However, this analysis is more difficult to apply due to the variability 
seen at the beginning and later stages of disease progression. Identifying when an individual is at 
the chronic phase of infection can be difficult to assess. In addition, this measure requires a long 
follow-up time with multiple data points for each patient to provide accurate results.28 Moreover, 
factors such as other infections, stress and drugs can highly affect absolute CD4 counts, which 
could introduce further noise.
2.4. Potential prognostic factors influencing disease progression
There is a large volume of literature that has been published on the topic of HIV disease 
progression. This literature review focuses solely on demographic variables, behavioural factors 
and clinical variables, covariates that were available to be studied in this research. Please refer to 
the methods section for further details on those variables. This review does not attempt to include 
all papers written on the subject, but rather provides an overview of the topic.
2.4.1. Demographics 
Research in the field of HIV disease progression commonly assesses the effects of demographic 
variables.  These variables are repeatedly studied due to the disparities seen in the number of 
HIV and AIDS cases across the various demographics.  As mentioned previously, males, 
20
Aboriginal persons, and those aged 30-39 at diagnosis are more prevalent than females, non-
Aboriginal persons and those of other age groups in Canada’s HIV & AIDS diagnosed 
population.1 A review of these demographic variables is written below. Due to the limited 
research in disease progression within Canada, most of the literature focuses on other countries.
Age 
Age, typically defined as age at HIV diagnosis (or seroconversion), is well acknowledged to 
effect disease progression. Older age has repeatedly been found to be associated with poorer 
survival and faster progression.23, 29-35 For example, a Canadian study found men aged 30 and 
over experienced a mortality risk about 50% higher than men under 30 years of age,33 while 
another study found an increased risk of death at a rate of 2% per year of age.30 Age has been 
shown to be a significant predictor of survival and disease progression independent of gender, 
exposure category, ethnicity, prior treatment and CD4 counts.29, 30 
While not fully understood, several biological factors associated with age are believed to 
contribute to this more rapid course.  Aging is associated with an increase in co-morbidities, 
which are believed to impact disease progression and survival.36 Similarly, age is correlated with 
diminishing immune function, another factor likely to effect progression.31 A study by Geskus et 
al37 highlighted this by showing that at similar times from seroconversion older age was 
associated with lower CD4 counts.  
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Due to the importance of age at diagnosis, it would be beneficial to quantify the influence of age 
on HIV disease progression in this study’s population. Furthermore, it would be necessary to 
control for this potential confounder in the analysis.
Gender
Mostly sex, and sometimes gender, are terms applied to the study of the variables ‘male’ and 
‘female’ in HIV disease progression analysis. However, before commenting on the findings of 
these studies, it is important to define these two distinct but inextricably interconnected 
constructs and explain why it is important to acknowledge these differences.  
As defined by Johnson et al,38 sex is “a multidimensional biological construct that encompasses 
anatomy, physiology, genes, and hormones, which together affect how we are labelled and 
treated in the world.” The researchers contrast gender as “a multidimensional social construct 
that is culturally based and historically specific, and thus constantly changing. Gender refers to 
the social prescribed and experienced dimensions of femaleness or maleness in a society, and is 
manifested at many levels.” In essence, it is a distinction between biological sex and the social 
conventions, roles and behaviours regarding that biological sex. For instance, once exposed to 
HIV through heterosexual contact, women are more likely to acquire the virus than men, due to 
the biological physiologies. Moreover, in cultures where gender inequities are present, varying 
powers to negotiate around sex may also increase the risk of transmission for women.  In these 
two examples, the risk of exposure is gender-linked while the risk of acquisition is sex-linked. It 
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is in the understanding and applying of these two constructs to health research that will yield 
more comprehensive science which in turn informs policy and effective programs.38
It is thought that the ‘male’ and ‘female’ dichotomy routinely collected in questionnaires 
provides both the sex and gender of individuals, given the interconnectedness of these two 
structures.38 Prins et al thus suggests that, “there is no difference in the use of the binary 
variables of sex and gender. The distinction between the two terms is usually relevant only when 
the mechanisms of influence are being studied.”39 The variables available for this study do not 
provide for an analysis of the mechanisms that may influence potential differences between men 
and women. Furthermore, sex or gender based analysis is currently lacking in the field of HIV 
disease progression. Sex and gender are incorrectly interchanged in much of the research, with 
sex being the more dominate term in this literature. When differences are noted, researchers tend 
to relate to social constructs as possible suggestions for the inequities. Give the greater support 
for the latter option, as is touched upon in the literature review, gender was chosen as the term to 
use for this study. However, it is entirely possible that biological factors may be the cause or 
could contribute to the potential differences observed.
The binary variable of ‘male’ and ‘female’ is commonly collected and included in HIV disease 
progression analysis. However, the effects of this variable are highly variable and inconclusive.  
The literature review is presented in two parts, studies pertaining to the pre-HAART era and 
those pertaining to the post-HAART. This was done given the large impact treatment has had on 
HIV disease progression.  These two lines of studies tend to also provide different information.  
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Pre-HAART studies inform on the natural course of HIV disease progression, while post-
HAART studies tend to relate to beneficiary outcomes of treatment. Of course, post-HAART 
studies can choose to focus on treatment naive cohorts, and thus would also obtain information 
on the natural history of progression. 
Since early on, studies were examining the effects of gender on disease progression. A total of 20 
studies were found to have assessed gender in the pre-HAART era. While the majority of studies 
found no significant effects,30, 32, 40-53 a few studies did find an association.35, 54-56 All but one of 
these studies54 were prospective cohorts from the United States, and they found that men had a 
lower risk of progression from HIV or AIDS diagnosis. The remaining study, by Prins and 
colleagues,54 was one of seven seroconversion cohorts. While Prins et al. combined 8 European 
IDU cohorts, its sample size was comparable to other seroconversion cohorts. In contrast to the 
three US studies, this study found women were at lower risk of progression to AIDS, but no 
differences were observed for mortality.  In general, while some studies did show differences in 
progression rates, when adjustments were made for factors such as socioeconomic status and 
health care utilization these differences disappeared, similar to what others have concluded.57
An additional six studies were identified that assessed this particular topic in the post-HAART 
era. Again, a minority of the studies found a significant association58, 59 while the rest did not.60-63 
The two former studies were based on US surveillance data, which did not contain information 
on treatment use or adherence and thus represented more crude statistics. Interestingly, 
Grigoryan et al58 focused on IDUs from 33 states and found women were at a lowers risk of 
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AIDS and death, which was in contrast to Hall et al59 findings. For the entire population (i.e. not 
only IDUs), Hall et al found men appeared to have better outcomes.  
Eight additional studies examined gender extending across both eras. All but one study, by 
Poundstone et al,64 were based on a seroconversion cohort. Four of these were larger studies 
composed of up to 38 different cohorts from Europe, Australia and North America. This 
expanding cohort has been termed Concerted Action on SeroConversion to AIDS and Death in 
Europe (CASCADE). The first, in 2000, consisted of 5893 seroconverters from European 
countries and Australia and found no differences in survival on the basis of gender.65 The second 
CASCADE based study in 2000, included additional cohorts resulting in a sample size of 13 030 
patients, did find a lower risk of death and AIDS progression for women compared to men. 
However, this was no longer the case when analysis was restricted to IDU and HC.66 In 2003, 
analysis was restricted to IDUs, and they observed a lower risk of death for women in 1999-2001 
compared to men.67 This was not noted in the period prior to 1999. Again, in 2008, including all 
cases, researchers noted women had slower progression to AIDS & death in the post-HAART 
era, something not noted in the pre-HAART era.  They found a 24% lower risk of AIDS and 32% 
lower risk of death in women compared to men from 1997 onward. This study highlights that 
while the possibility for a biological factor accounting for these differences is possible, changes 
over time are more likely attributable to external changes, such as the environment. 
Two other studies were from a Spanish cohort, termed Spanish Multicentre Study Group of 
Seroconverters (GEMES). The first study was published in 2003, and it noted women IDU had a 
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slower progression to AIDS and death than men IDUs. Attempting to further explore these 
results, the second study in 2004 further controlled for educational level.68 Results became 
marginally significant. Finally, the remaining two studies were US based. Sterling et al noted no 
differences in their seroconversion cohort.69 Poundstone et al did find men to have a lower risk of 
opportunistic infections or death than women in a seroprevalent cohort.64 In total, half of the 
studies found significant differences.
Although these disparities have been shown to exist, there tends to be a general consensus that 
gender is a function of a social construct and not biological. Therefore, while crude data may 
show differences in progression, after adjusting for confounders these differences tend to 
disappear. This is highlighted in the latest literature review conducted in 2005. Prins, Meyer, and 
Hessol70 concluded that there was little evidence for sex differences in the rate of disease 
progression in both the pre- and post-HAART eras indicating there were no differences in the 
natural course of HIV or in the benefits of antiretroviral therapy. In reviewing settings with 
acceptable gender equity in access to care, women have been reported to be healthier, more 
likely to exercise health-seeking patterns, and have higher rates of adherence compared to men, 
which could potential explain the differences observed.70-73   
In Canada we tend to find an over representation of males in our HIV population (5:1 ratio). 
However, Saskatchewan has the lowest male to female ratio (3:2) compared to the other 
provinces.1 In acknowledging this province’s unique characteristics, it is important to identify 
how gender may be impacting progression of the disease.
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Ethnicity
Similar to gender, ethnicity has always been of interest due to the disparities seen in prevalence 
and clinical outcomes in the various ethnic groups since the beginning of the epidemic.  
Historically, HIV and AIDS disproportionately affected minority groups in North America, and 
these minorities had consistently shown less favorable clinical outcomes.74, 75 Currently, this 
trend continues to exist and a review of the crude national statistics in America clearly highlights 
this point.43, 58, 59, 76 The magnitude of these ethnic disparities also appear to be increasing. While 
survival has dramatically increased largely due to the widespread use of HAART, these 
beneficial effects have not been uniformally distributed.  American data found hazard ratios for 
survival for AIDS-diagnosed non-Hispanic blacks compared to whites increased from 1.18 in 
1993-1995 to 1.51 in 1996-2001, a 33% increase.77 This increased risk was not due to a faster 
progression in non-Hispanic blacks, but as a result of the decreased progression rate in the whites 
due to treatment.77 These growing disparities have consequently led to researching the 
association of ethnicity and disease progression. 
Studies in both the pre-HAART and post-HAART era have found inconsistent results.  
Unadjusted results for some studies found ethnicity to influence disease progression,45, 60, 62, 78-81 
but not all.5, 35, 40, 50, 63, 64 The vast majority of these studies were from the US. In general, 
minority groups, such as blacks and Hispanics were shown to have unfavorable outcomes 
compared to whites.  However, when adjusting for potential confounders such as treatment, age, 
and clinical status at baseline, however, these differences disappeared. 
27
It is difficult to draw conclusion given the inherent limitations of these studies.  All of the studies 
were based on seroprevalent cohorts, with varying study designs and definitions of ethnicity/
race. One of the more rigorous studies was a multi-centre randomized control trial composed of 
1357 treatment naive patients initiating HAART.60 This study found that at enrollment, African 
Americans had lower CD4 count, more likely to have history of AIDS and hepatitis C compared 
to whites. Adherence scores were also lower in African Americans than whites.  When adjusting 
for all these differences, ethnicity was no longer a predictor of AIDS diagnosis or death. These 
studies seem to suggest that disparities in HIV disease progression are more likely the result of 
social and not biological factors. Differences observed could be reflective of differences in 
access and use of health care for minority groups compared to whites, particularly when these 
studies are based in a setting without universal health care.  
It is important to note a Switzerland study that found contrasting results.82 This study compared 
follow-up data of 586 treatment naive HIV residents. African descent was associated with a 
slower decline in CD4 cell counts compared to European descent (+26.6 cells/yr., p<0.001). The 
decline in CD4 cell count was not found to be dependent on baseline VL for those of African 
descent. The authors state that these results could point to a potential tolerance of high virus 
levels in patients of African descent. Two American studies have also found this association,55 
one within a subgroup population.35 With this findings in mind, it is quite possible that both 
social and biological factors may play into ethnic disparities. Teasing apart the effects of these 
two factors, however, is a definite challenge.
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Aboriginal Ethnicity
In Canada, the ethnic group of Aboriginal people experience wide disparities in health compared 
to their non-Aboriginal counterparts. Mortality and morbidity rates of Aboriginal people are 
higher than in the general Canadian population.83, 84 Aboriginal people also tend to have lower 
family income, lower education attainment, and inadequate housing,85, 86 indicators of a lower 
socio-economic status, which have been linked directly to health.87  These disparities in the 
health status of Aboriginal people have been traced back to Aboriginal-specific historical 
contextual factors such as colonization and racism,88 which have been linked directly and 
indirectly to adverse health outcomes for Aboriginal people.87, 89
These health disparities are also very evident in the field of HIV.  As mentioned previously, 
Aboriginals are disproportionately burdened by HIV/AIDS in Canada. While Aboriginal people 
account for only 3.8% of Canada’s population, they constitute 16.2% of all HIV cases in Canada 
from 1984 to 2008.1 Aboriginal people make up a unique segment with different characteristics. 
In comparison to non-Aboriginal people, HIV positive Aboriginal people tend to be younger and 
have a higher proportion of women, with IDU being the dominate driver of transmission. These 
characteristics raise further issues such as pregnancy and mother to child transmission.90 Due to 
these unique characteristics and the vulnerabilities linked to the social determinants of health, it 
is important to examine the effects of Aboriginal ethnicity on disease progression.
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A review of the literature yielded one study focused on Aboriginal people and disease 
progression. This study, from British Columbia, Canada, was based on a longitudinal cohort. The 
findings showed that Aboriginals persons had all-cause mortality rates 3.12 times higher than 
non-Aboriginals.80 This study was able to control for many potential confounders including 
treatment and adherence, in addition to equal health care access. The all-cause mortality rate was 
associated mainly with HIV-related causes. Co-morbidities, however, were not controlled for in 
the study. One additional US study should be noted. This study by Diamond et al79 compared 
American Indians/Alaska Natives (AI/AN) to non-AI/AN from three western metropolitan cities 
in the US.  AI/AN ethnicity was found to be predictive of a slower progression to clinical AIDS 
compared to non-AI/AN but not for immunological AIDS (i.e. CD4 counts below 200).  In the 
adjusted model, however, no differences were seen between the two groups. This study, however, 
is limited chiefly by its inability to compare between the various ethnic groups, but rather pooled 
54% Whites, 20% Blacks, 22% Latinos and 2% Asian and Pacific Islanders into one category 
and compared it to the 1% AI/AN, which likely diluted any potential differences. No studies 
incorporating Aboriginal ethnicity were found to examine time to AIDS.
There is reasonable conjecture to believe that Aboriginal people may have a more rapid 
progression that non-Aboriginal people.  In efforts to understand why there is a high proportion 
of Aboriginal people, much research has focused on the antecedent risk factors of HIV 
acquisition. Aboriginals people appear to have an increase of antecedent risk factors for HIV 
infections, such as sexual abuse, history of IDU, poverty, poor mental health and involvement in 
the sex trade.91-93 Unfortunately, HIV infected Aboriginals are also more like to suffer from other 
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morbidities, including Hepatitis C co-infections, and depression.80 Aboriginal ethnicity has also 
been shown to be associated with a lower likelihood of HIV treatment.94 All of these factors have 
been linked to poor outcomes in disease progression.
In summary, there is limited research on this topic providing a lack of understanding on the  
influences of Aboriginal ethnicity on disease progression.
While examing Aboriginal ethnicity, the author acknowldegdes that precautions need to be 
undertaken when dealing with ethnic data. While aiming to better characterize the natural history  
of HIV positive patients researchers must be aware that differences in ethnicity may be simply 
due to differences in socioeconomic factors, which may be a much better predictor of 
differences. Also, it must be noted that differences observed could lead to increased 
discrimination or stigmatization of particular ethnic groups. On the other hand, failure to address 
ethnic difference may have severe consequences.  Ignoring ethnicity would prevent the 
acquisition of knowledge of disparities in health among ethnic groups. It would weaken the 
efforts of public health to properly respond. Furthermore, inadequate knowledge would give 
false reassurance, and most importantly could lead to further marginalization of vulnerable 
groups. 
2.4.2.  Behavioural factors
More recently the effects of poor health behaviours, such as substance abuse (e.g. injection drug 
use) and smoking, have began to be examined. There is great interest in looking at these factors, 
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because while other cofactors, such as age or genetic composition, are not alterable, lifestyle 
factors are modifiable. It must be noted that there are other variables that are showing potentially 
important associations with HIV disease progression, such as alcohol use.95 However, this 
literature review will only focus on those variables which are available to be assessed in this 
study. Presented below is a review on the effects of drug use and smoking on disease 
progression. 
Drug use 
Drug use is associated with many harmful consequences including health problems.  It is not 
surprising that the potential impacts of drug use have been of interest with regards to disease 
progression. Raw data, as expected, shows IDU is association with a higher risk of mortality.  
For instance, US national data showed that male IDUs were at a greater risk for death than men 
who have sex with men (MSM).59 More recent analysis of 33 US states from 1996 to 2004, 
found three year survival after HIV diagnosis was lower for IDU males than males exposed 
through male-to-male sexual contact or high-risk heterosexual contact. Survival was also lower 
for IDU females compared to high-risk heterosexual contact females. The analysis controlled for 
race, age, CD4 cell count at diagnosis, concurrent diagnosis of HIV and AIDS, metropolitan 
residence and diagnosis year.58 
Strong support from the harmful effects from drug use come from studies based in basic science.  
In vitro research has highlighted that drugs including morphine, cocaine, and marijuana up-
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regulates the growth of HIV.96, 97 Cocaine has also been shown to cause immune alterations and 
interfere with the body’s defenses suggesting that it may directly affect the pathology of HIV.98, 99 
However, epidemiological research on this topic has yielded inconsistent results. Most rigorous 
prospective studies with seroconversion cohorts have found no differences in progression to 
AIDS or death.29, 53, 65, 66, 100 Two of these studies, published in 2000, were based on the 
expanding CASCADE cohort. Interestingly, a third study based on the CASCADE cohort was 
published 3 years later with contrasting results.67 In the pre-HAART era, IDU had a lower 
adjusted hazard ratio for AIDS than MSM (HR: 0.74; 95%CI: 0.64-0.86). This reversed in 
1999-2001 with an adjusted HR of 2.76 (95%CI: 1.87-4.06). Similar results were seen for 
survival analysis. While these studies have large sample sizes and are based on seroconversion 
cohorts, they do have a few key limitations. First, they have utilized the transmission mode of 
IDU as a proxy for drug use. This results in a possible misclassification bias as it excludes drug 
users who do not inject. Second, the comparison group of MSM may be inappropriate as we 
know that they tend to have different characteristics (see below). And finally, there is a lack of 
control for important confounders such as access to and adherence to treatment. What most 
studies do consistently report is that IDU exposure category is associated with a lower reduction 
in risk to AIDS and death compared to the other exposure categories (MSM and HC) in the post-
HAART era compared to the pre-HAART era.67, 72, 101 Additional prospective cohort studies 
focused on IDUs have noted substantial pre-AIDS morbidity and mortality compared to other 
transmission categories.102, 103 
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In effort to further explore drug use, other measures have been used. For instance, three 
seroprevalent studies have tested the association between frequency of drug use or current versus 
former drug use. Similarly, no differences were seen between these measures.52, 104-106 Other 
studies have focused on the type of drugs.  In a large US longitudinal multi-center cohort of 1686 
women, crack cocaine use was shown to be an independent predictor for AIDS-related mortality, 
immunologic and virologic markers of HIV-1 disease progression and the development of AIDS-
defining illnesses.107 Specifically, they found persistent crack users had an adjusted HR of 1.65
(p<0.05) and intermittent crack users had an adjusted HR of 1.57 (p<0.01) for AIDS compared to 
nonusers. The hazard ratio for mortality was 3.61 (p<0.001) for persistent crack users than non-
users, but no difference for intermittent users. This study was able to control for many important 
confounders including treatment adherence and socioeconomic status. Two other studies have 
similarly found crack-cocaine to be associated with AIDS.46, 108 Hallucinogen use has also been 
significantly associated with both AIDS diagnosis and death in another US study. 109 In this 
study, cocaine use was only associated with a higher risk of death. A combination of crack 
cocaine and marijuana has also been shown to increase the rate of progression to CD4 count 
<200 cells/ml to 2.42 times higher, when controlling for ART and alcohol.108 
A critical review by Kapdia et al110 in 2005 attempted to reconcile difference between laboratory 
and epidemiological investigations with regards to the role of substance abuse in HIV disease 
progression. The authors note that epidemiological studies have key methodological issues. As 
mentioned previously, comparing IDU to MSM is problematic in that MSM tend to have 
different characteristics, such as higher socioeconomic status than IDUs. Furthermore, IDU are 
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more likely to experience non-AIDS-related mortality due to overdose, violence and accidents 
potentially masking differences between IDU and non-IDUs. Lastly, IDUs enrolled in cohorts 
may be healthier and better able to manage their drug use, thus progressing to AIDS or death less 
rapidly. The authors concluded that findings from both of these fields indicate that the 
relationship between drug use and HIV disease progression may be “mediated by several key 
factors, including immunological and virological conditions affecting host susceptibility, 
underlying co-morbidities among drug users, use of antiretroviral therapy, and viral strain, as 
well as pharmacodynamic aspects of drug use, such as the pattern and type of drug 
administration and the route of administration.”110
In summary, while laboratory studies do seem to provide reasonable support for IDU potentially 
adverse effects on progression, epidemiological studies provide mixed results.  Studies focused 
on IDU found minimal differences, while studies focused on other routes of administration found 
more significant results. Certain methodological limitations may account for differences seen 
between these two lines of research. 
Smoking
Similarly to drug use, smoking is another life-style factor that is more common among those with 
HIV compared with the general population.111 In parts of Canada, smoking prevalence was three 
times higher for HIV positive individuals than that of the general population.112 As such, it is 
important to examine its potential effects on disease progression, and few studies have done so.
35
In 2006 a systematic literature review was conducted on this topic by Furber et al.113 Included 
were 10 studies using progression to AIDS as an endpoint, in which nine found no relation with 
tobacco smoking. The authors did note that most of the studies were done in the pre-HAART ear 
and were conducted over a short follow-up period.  With the increased life expectancy due to 
HAART, it is possible that the smoking may now cause inter-current illness, which could 
contribute to general debilitation and progression to AIDS. More recent research has shown that 
inter-current illnesses are more frequent in smokers compared to non-smokers among those HIV 
positive.112
Additional studies were since published.  Three of these studies focused on the incidence of 
respiratory-related infections (tuberculosis, bacterial pneumonia, and pneumocystis carinii 
pneumonia), some of which are considered AIDS-defining illnesses.114-116 All three found an 
increased relative risk of getting these respiratory infections ranging from 1.56 to 2.55 higher for 
smokers compared to non-smokers. The final study examined declines in CD4 cells and found an 
increased risk of developing AIDS (HR, 1.36; 95%CI, 1.07-1.72) among smokers compared to 
non-smokers.117 Three studies also assessed the effects of cigarette smoking on mortality.  All 
found an increased hazard ratio for all-cause mortality (ranging from 1.53-1.99) when comparing 
current smokers to never smokers.115, 117, 118 
In summary, owing to the increased life expectancy in the post-highly active antiretroviral 
therapy ear, smoking is likely an increasingly important contributor to morbidity and mortality in 
HIV infected populations.119 Furthermore, the high prevalence of smoking in Saskatoon’s HIV 
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positive population makes it even more important to examine this life-style factor influence on 
disease progression. 
2.4.3. Clinical factors
Co-morbidities not only reduce the quality of life for HIV infected persons, but may also be 
influencing disease progression.  Numerous studies have shown certain co-morbidities were 
associated with HIV disease progression.120-123
 
Hepatitis C Co-infection
Due to the shared modes of transmission, Hepatitis C virus (HCV) co-infections are high among 
HIV positive IDUs, with a prevalence of 50-80% in Western Canada.124, 125 A high proportion of 
Saskatchewan’s HIV population are IDUs,15 and consequently HCV co-infections are a 
significant problem for this province.  Thus, this potential risk factor is important to 
address.  
HIV infection has been associated with faster progression of HCV-related liver disease,126 
however, the effect of HCV infection on the progression of HIV are less clear.  While numerous 
studies have found an association127-131 other have not.132-135 
A recent meta-analysis examining the effect of HCV infection on HIV disease progression and 
overall mortality was conducted. Based on 27 studies in HAART era, the authors calculated that 
HCV co-infection was associated with a 35% increased risk of mortality, but not the risk of AIDS 
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defining events.136  The adverse effect of HCV co-infection was more apparent with longer 
follow-up and among patients who were receiving HAART than those not receiving HAART.  
Two of these studies adjusted for IDU, a common confounder in HIV and HCV co-infected 
cohorts, and found the negative effects of HCV infection on mortality were independent of IDU.  
One key limitation of these studies is that all ascertained HCV infection status through antibody 
level, and could not control for HCV viral load or patients who experienced a spontaneous 
clearance of HCV without treatment, common among 25% of adults infected with HCV.137  
In attempts to address the inconsistent findings, one detailed study in 2010 examined the effects 
of viremic load and immune activation.138 It is hypothesized that immune activation, induced by 
an infection, leads to lengthened HIV replication period and consequently an accelerated disease 
progression, as has been seen with other co-morbidities.139, 140 This study, focused on a US 
prospective cohort of women, found that HCV viremia was associated with AIDS outcome, 
independent of injection drug use, HIV RNA level, CD4 count and ART. Furthermore, the 
authors found HCV viremia was associated with CD4 and CD8 activation, independent of HIV 
RNA level. Finally they also showed that high levels of CD8 activation were associated with 
AIDS in HCV-positive viremic women but not in HCV negative women.  
In summary, the literature overall does appear to suggest that HCV has adverse effects on HIV 
and HCV co-infected patients compared to those HIV mono-infected. However, while limited 
research does show influences on HIV disease progression to AIDS, a more substantial effect on 
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overall mortality is seen. Given the high prevalence on HCV among Saskatchewan’s HIV 
population, this is an important risk factor to consider.  
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3. Methodology
3.1. Theoretical perspective & conceptual framework
This section provides a brief introduction into the theoretical perspective and conceptual model 
that framed this study. The theoretical perspective provides information as to the ideologies and 
philosophical ideas that explain health, while the conceptual model provides the 
operationalization of the theory for this study. 
Numerous theoretical perspectives of disease or health exist to explain or predict a certain 
phenomena. Within the field of HIV, two commonly competing theories are present. Social 
production of disease is an epidemiological theory that “conceptualizes determinants of disease 
distribution as economic and social relationships forged by a society’s political and economic 
structure.”141 The structure of the society results in a variety of social groups that are 
differentially aided or hindered by their position relative to others.  
Within the realm of HIV research, this theory has been utilized to explain the distribution of 
HIV and AIDS. For instance, risk of acquisition of HIV is characterized by economic deprivation 
and racial discrimination.142-144 Thus, “hypothesis emerging from this theory proposed 
explanations of HIV transmission in relation to social class, access to health-related resources, 
work place conditions, and discrimination based on gender, ethnicity, sexual orientation/identity 
or other attributes.” 141
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A common competing theory in the field of HIV is the life-style theory. This theory postulates 
that determinants of disease occur as a result of behavior clusters or cultural factors that are 
shared among individuals.141 For instance, homosexual men were believed to have a life-style 
conducive to HIV acquisition.145 In essence, it suggests that an aggregate of individuals make 
choices, and that these choices thus determine the distribution of disease at a population level. A 
key component of this theory is that if these are individual choices, these choices are also 
amendable to change, which is the foundation for many HIV prevention programs.146
The two theories presented are at opposite ends of the spectrum, and positioned within is where 
this research lies.  This researcher acknowledges that both the social and economic factor and 
individual factors affect the distribution of health.  In fact, these two views are seen as mutually 
inclusive.  Individuals are not self-contained units, but are highly influenced by their social 
structures.  Similarly, political and economic structures do not solely determine individual 
choice. In other words, neither influence health in isolation, but it is the interplay between these 
two factors that determine health. 
Conceptual framework
The Etches Pyramid is a paradigm for health research, developed in 2006.147 This paradigm, like 
many others, acknowledges that many interconnected aspects of society, the environment and 
individuals all contribute to the status of health.  Integrated in the framework are macro- or 
upstream factors that affect the health of the population and individual, such as political and 
social influences. Also included are the meso- and micro-levels of causal analysis, which include 
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biological factors and more proximal causes of health such as genetic predispositions and 
lifestyle factors.  
The life-course process is another key concept incorporated in the Etches Pyramid.  This life-
course perspective is an approach used to analyze people’s lives within structural, social and 
cultural contexts. This approach accounts for an individual’s history and examines how these 
earlier events influence various outcomes – in this case, health. A life course perspective is 
thought to contain both a ‘critical period’ and an ‘accumulation of risk’ perspective. The critical 
period refers to exposures acting during a specific period that have subsequent long-lasting 
effects on the future health of the individual. Accumulation of risk refers to an additive effect of 
continuous adverse exposures through-out life. Risk can also be thought to be chained together, 
such that one adverse exposure tends to lead to another in a sequential manner.  For instance, 
poverty tends to be followed by poor education and unemployment. Life course is not limited to 
the individual, but can reach across generational effects.148
My proposed research relies on this integrated framework in which health is considered within 
both a temporal and hierarchical framework in a mutually inclusive manner. Presented below is a 
conceptual model that addresses specific determinants that were examined in this study of HIV 
disease progression (Figure 3.1). This conceptual model acknowledges that risk factors are 
operating concurrently at various hierarchical levels from the macroeconomic to the molecular. 
However, this conceptual model is simplified into proximal and distal influences on health. 
Biological factors and health behaviours are considered to be proximate level risk factors. The 
distal factors would include the wider upstream factors that would also directly and indirectly 
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impact the health of the individual. Bridging these two spheres are the social and physical 
environment. In this schema, proximal factors are not considered equivalent to individual factors, 
as individuals are recognized as social and contextualized persons and therefore their 
characteristics and behavioural choices are considered in-light of their surroundings.149, 150 As 
above, these factors, do not exist in isolation, but rather continuously interact to create complex 
levels of health status. 
Figure 3.1.  HIV disease progression conceptual model
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Embedded within this multi-level framework is the life-course perspective. In examining 
ethnicity and gender, it is important to acknowledge historical and possibly intergenerational 
influences. Furthermore, there is an understanding that behavioral factors and clinical outcomes 
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are shaped by experiences early in life and throughout the life-stages.151 Risk acquisition evolves 
over time through a cumulative and interactive process. 
While this study can only focus on certain proximate risk factors, their biological mediators and 
more distal factors are recognized as important influential domains. For instance, many viral, 
host and environmental factors have been identified to influence disease progression. Viral 
factors encompass the genetic variability of HIV, including viral subtypes152 and viral 
phenotypes.153, 154 Genetic variability of the host, such as the CCR5 Δ32 mutation, and immune 
function can also come into play. Lastly, all of these factors are found to interact with the 
environment which can include variables such as availability of adequate medical treatment11 
and the coexistence of TB.155  All of these factors interact to create a complex and multifaceted 
environment that determines the rate of disease progression.  
In summary, although this research was undertaken with an understanding of the complex multi-
level model, examining the effects of all potential factors is not feasible. Thus, while all 
components play important roles, host factors, particularly demographic variables, behavioural 
factors, and clinical variables are more readily identified. As such, they could potentially 
contribute more information. Due to the availability of these factors such as demographics this 
research will focus on these proximal variables.
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3.2. Study design
The research is a retrospective longitudinal cases-based study. Data collection comprised of data 
extraction from medical charts of the most recently diagnosed HIV positive patients at the 
Positive Living Program (PLP) and West Side Community Clinic (WCC) in Sasaktoon, 
Saskatchewan, Canada. 
3.3. Setting and population
Saskatoon is the most populous urban center in the province, located in central Saskatchewan, 
Canada. Saskatoon’s population is composed of 10% Aboriginals, and 7% other visible 
minorities.85 In Saskatoon, the PLP and the WCC are the only sites specialized in HIV/AIDS 
care. 
The PLP, located at the Royal University Hospital, serves adults and children with HIV and/or 
Hep C who reside in central and northern Saskatchewan, with the exception of one other site in 
Prince Albert. A distribution of patients from the PLP in 2007 showed that 59% of patients were 
from Saskatoon, 13% from Prince Albert, and the remaining 28% from other areas. Individuals 
are referred to the PLP by Public Health, private physicians, or through self-referrals. This study 
focused only on HIV positive patients at the PLP. 
The WCC serves the core residents of Saskatoon, primarily marginalized populations such as 
Aboriginals, the elderly and the economically disadvantaged.156 The WCC therefore does not 
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solely function as an HIV/AIDS clinic but rather as a community clinic, which is highly 
burdened by HIV, as exemplified in the case load. Given that HIV has disproportionately affected 
marginalized populations, as of March 2010, the clinic had a case load of 204 clients, a 105% 
increase from the previous year.157 Again, this study focused solely on HIV positive patients at 
the WCC.
3.4. Operational and ethics approvals
Approval to collect data from the WCC occurred early in 2010 by a separate individual working 
on a related project. Operational and ethics approval documents were drafted, submitted and 
approved during the summer of 2010 for data collection at the PLP site. Following both approval 
processes, an amendment was submitted requesting approval to combine and use both datasets, 
which was granted. 
3.5. Data collection
The WCC data was collected from May to July 2010. Data collection at this site began with the 
most recently diagnosed HIV patients and moved backwards to earlier cases up to 2007, which 
represented the majority of HIV cases attending the clinic. The data collected at this site was 
directly recorded into a password protected excel dataset. Data items included information on 
demographics (age, sex and ethnicity/race), HIV diagnosis data (date of HIV diagnosis), HIV 
risk factor (IDU, MSM, HC, etc.), past medical history, co-morbidities, HIV treatment, and 
laboratory data (CD4 cell counts, CD4% and VL, along with other diagnostic laboratory results).
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For the PLP, data extraction was conducted from August to December 2010. Data collection 
began with the most recently diagnosed HIV patients and moved backwards to earlier cases up to 
2005.  Data collection was directly recorded into a password protected excel dataset. Data items 
included information on demographics (age, sex and ethnicity/race), HIV and AIDS diagnosis 
data (date of HIV and AIDS diagnosis), HIV risk factor (IDU, MSM, HC, etc.), past medical 
history, co-morbidities, HIV treatment, and laboratory data (CD4 cell counts, CD4% and VL, 
along with other diagnostic laboratory results). 
Data extraction at the PLP was modeled after data extraction tools at the WCC. There were a few 
additional variables that were collected for the PLP site and not the WCC. These include, AIDS 
diagnosis (date and AIDS defining illness), date of initiation and termination of ART treatment, 
and smoking status. 
Two standardized medical forms were central in extracting specific data. The first was an ‘HIV 
Case Reporting Form,’ a standardized provincial report form. This form includes patient 
information (i.e ethnicity, date of birth, and gender), HIV risk factors and clinical/laboratory 
data. All risk factors that apply are checked off. For a copy of this form, please refer to Appendix 
2. The form is filled out by the physician or nurse with the assistance of the patient. The other 
form was the Saskatoon Health Region ‘HIV Initial Assessment’ form. Similar to the form, it 
includes patient information (i.e. ethnicity, date of birth, and gender) and risk factors. In addition, 
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this form records the previous HIV negative serology. Please see Appendix 2 for a copy of this 
form. Again, this form is completed by the physician or nurse with the assistance of the patient. 
Specific details as to the variables collected are described below:
HIV diagnosis date (month & year) - was extracted from either the HIV Case Reporting Form, 
HIV Initial Assessment Form, or laboratory result.
AIDS diagnosis date (month & year) and AIDS defining illness - was extracted from the HIV/
AIDS Case Report by PHAC (see Appendix 2).
Date of death (month & year) and cause of death - was extracted from the HIV/AIDS Case 
Report by PHAC (see Appendix 2) or from any notations indicating this event within the 
medical chart.
Last negative HIV serology - was collected when the previous negative HIV serology test was 
present in the medical chart. The initial assessment form was recorded this information. This 
information was only used if a month and year was recorded.
Age at HIV diagnosis - was calculated from the month and year of DOB recorded in either the 
HIV Case Reporting Form, HIV Initial Assessment Form, any laboratory results, or other such 
reliable documents.
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Gender - was obtained from either the HIV Case Report or HIV Initial Assessment Form, 
which included ‘male’ or ‘female’ options.
Ethnicity - was collected from either the HIV Case Report or HIV Initial Assessment Form, 
which included: White, Black (e.g. African, Haitian, Jamaican, Somali, etc.), First Nations, 
Métis, Inuit, Asian (e.g. Chinese, Japanese, Vietnamese, Cambodian, Indonesian, Filipino, 
etc.), South Asian (e.g. East Indian, Pakistani, Sri Lankan, Punjabi, Bangladeshi, etc.), Arab/
West Asian (e.g., Armenian, Egyptian, Iranian, Moroccan, etc.), Latin-American (e.g. Mexican 
Central/South American, etc.), or other / mixed ethnicity (ethnicity is known but is not 
included in one of the above categories, or case has dual ethnicity).
HIV risk factors - were obtained from the HIV case report or the HIV Initial Assesment Form. 
For a complete list of all risk factors, please refer to Appedix 3.
Hepatitis C antibody - testing was done during the initial ‘entry visit’. If an indeterminate or 
positive antibody test resulted, PCR testing was ordered to determine if the patient was 
actively infected with hepatitis C.  These two data points were collected from the laboratory 
results. However, an earlier HCV test reported by the patient was also collected.
VL, CD4 counts, and CD4% - were ordered at the first visit and at various follow up visits as 
deemed appropriate by the physician. All VL, CD4 count, CD4% results were recorded as 
well as the corresponding date of collection of the specimen. 
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Comorbidity information - was generally collected in the HIV Initial Assessment Form. 
However, this data was collected if it was recorded at any point during follow-up.
Treatment information - was collected from physician’s visit notes or prescription copies keep 
in the file. This information was updated at every visit within its specified area in the follow-
up forms. Adherence, however, was difficult to assess as there was no standardized measure or 
a section to record this. 
Smoking status - was commonly written on follow-up forms, while there was no formal 
section for this information.
History of IDU - a significant number of cases did not mark IDU as a risk factor for HIV 
transmission, however indications of IDU were recorded elsewhere in the medical charts.  
These were combined with those reporting IDU risk factor, to create the history of IDU 
variable. 
Incarceration - was collected whenever there were indications the individual was incarcerated 
during follow-up.
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Social Assistance - was collected when copies of supplementary social assistance forms 
signed by the attending physician were present in the medical chart. Any additional 
information stating the individual was on social assistance was also used. 
3.6. Inclusion/exclusion criteria
All HIV positive individuals who were clients of the PLP or the WCC were eligible to be 
included in the study.  However, cases were limited to those diagnosed in or following the year 
2005.  This was done to obtain a manageable number for data collection and also to reduce the 
amount of missing data.  Those diagnosed more recently tended to have more complete records 
in their medical charts. In addition it would reduce bias introduced by temporal changes, such as 
new treatment.  Individuals under the age of 18 at HIV diagnosis were excluded in this study, as 
rates in progression have been shown to differ between children and adults.70  The inclusion and 
exclusion criteria are summarized below.
Inclusion criteria:
a) HIV positive individuals from the PLP or the WCC
Exclusion criteria:
a) HIV diagnosis prior to 2005
b) Children and youth ( <18 years of age at HIV diagnosis)
Due to the exclusion criteria, a number of cases were removed from the final dataset.  First, a 
total of 15 duplicates were identified and removed. Twenty two cases had a diagnosis date prior 
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to 2005 and were thus also removed.  An additional 3 cases had no year of diagnosis and were 
also excluded. Finally, an additional 10 cases were under the age of 18 years at diagnosis leaving 
a total of 343 cases. Figure 3.2 details the merging of the two datasets and the exclusion of cases.
Figure 3.2. Summary of inclusion process into study dataset
Duplicates    (n=15)
Dx prior 2005        (n=23)
Under 18 yrs old    (n=10)
PLP Dataset
 N = 223
WCC Dataset
N = 170
Combined Dataset
n = 393
Study Dataset
N = 343
IDU = 272
Non-IDU = 64 
(7 missing) 
HCV = 264
Non-HCV= 70
(9 missing) 
Aboriginal = 230
Non-Aboriginal =91
(22 missing) 
Males =177
Females = 166
(0 missing)
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3.7. Variable selection
The independent variables that were available for analysis are summarized in Table 3.1.  Some of 
these variables were not included in the study analysis for a number of reasons.  Residency was 
not included as this variable was poorly defined. Serological antibody tests, including Hep A, 
Hep B,  TB, and varicella, were not included as they may only indicate immunity due to 
immunizations and not prior infections. The frequency of active TB (confirmed by chest x-rays) 
were too small to be included.  The frequency of the other antibody tests were to numerous to 
allow for comparisons between those infected and those uninfected. Active IDU was difficult to 
assess, as active IDU was not commonly recorded. In addition, issues with social desirability 
response bias made this a weak variable and was therefore not included. The types of drugs 
reported were generally in multiples and were not included in the analyse. Incarceration was 
difficult to assess from medical charts, but was collected whenever reported. Methadone 
treatment was believed to not have analytical value for the study of disease progression as it did 
not include the duration of time on methadone and adherence to methadone.
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Table 3.1. Independent variables available in the database
Category Variable Description Type
Demographics Sex Female, Male, or Unknown Categorical
Age At diagnosis Continuous
Ethnicity Caucasian, First Nations, Metis, Inuit, 
African, Asian, Other
Categorical
Primary Residence First 3 digits of postal code Categorical
Secondary Residence First 3 digits of postal code Categorical
Exposure category Exposure categories Sex with a male, sex with a female, bisexual 
contact, sex with high risk partner, needle 
stick, immigrant from endemic area, IV drug 
use, other (acupuncture, tattoo, body 
piercing), commercial sex trade worker
Categorical
Medical History Co-morbidities List and date of onset/diagnosis if available Categorical
Family History List Categorical
TB mantoux test Date and result (most recent) Categorical
Active TB Yes, No, Unknown Categorical
Hep B Ab Yes, No Categorical
Hep C Ab Yes, No Categorical
Date of Hep C Test First Hep C test recorded Categorical
Hep C Positive PCR 
Test
Date
Hep C Genotype 1, 1a, 1b, 2b, 3a Categorical
CMV Ab Yes, No; first records at clinic entry Categorical
Toxoplasma Ab Yes, No; first records at clinic entry Categorical
HSV Ab Yes, No; first records at clinic entry Categorical
Varicella Ab Yes, No; first records at clinic entry Categorical
Syphilis Ab Yes, No; first records at clinic entry Categorical
Chlamydia Ab Yes, No; first records at clinic entry Categorical
Gonorrhea Ab Yes, No; first records at clinic entry Categorical
Opportunistic 
Infections
PCP Date Laboratory confirmed Continuous
MAC Date Laboratory confirmed Continuous
OHL Date Physician diagnosis, or laboratory confirmed Continuous
Candida Date Physician diagnosis, or laboratory confirmed Continuous
MRSA Yes, No (and date if available)
Other Infections List and date of diagnosis 
Social Active IDU Yes, No; within last 6 mo of follow-up Categorical
History of IDU Yes, No; ever IDU Categorical
Methadone Treatment Yes, No, Referred; ever Categorical
Substance Abuse List of types of drugs used
History of 
Incarceration
Yes, No Categorical
Smoking Status Current, Former and Ex-smoker Categorical
ART Treatment History of ART Yes, No; ever Categorical
ART Type, date of initiation and termination Categorical
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The independent variables used in this analysis are summarized in Table 3.2. These variables 
were chosen because of their potential influence in disease progression as identified by the 
literature review.
Table 3.2. Independent variables used in data analysis
Category Variable Description Type
Demographics Sex Female, Male, or Unknown Categorical
Age At diagnosis Continuous
Ethnicity Caucasian, First Nations, Metis, African, 
Asian, Inuit, Other
Categorical
Exposure category Exposure categories Sex with a male, sex with a female, bisexual 
contact, sex with high risk partner, needle 
stick, immigrant from endemic area, IV drug 
use, other (acupuncture, tattoo, body 
piercing), commercial sex trade worker
Categorical
Medical History Co-morbidities List and date of onset/diagnosis if available Categorical
Date of Hep C 
Antibody Test
First Hep C test recorded Categorical
Hep C Positive PCR 
Test
Date
Social History of IDU Yes, No; ever IDU Categorical
Smoking Status Current, Former and Ex-smoker Categorical
Incarceration Record of during follow-up, Yes or No Categorical
Social Assistance Record of during follow-up, Yes or No Categorical
ART Treatment History of ART Yes, No; ever Categorical
ART Type, date of initiation and termination Categorical
Risk factors were categorized according to PHAC’s  exposure category hierarchy.  Individuals 
having a positive HIV test may report more than one exposure category for acquiring the 
infection. These individuals are assigned to the exposure category with the highest probability of 
transmission. See Appendix 3 for the hierarchy list of risk factors. Baseline CD4 count was 
defined as the first CD4 cell count within 6 months of diagnosis.
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3.8. Dependent variables
For this project, disease progression was defined as the time to an event of interest. Those events 
of interest where immunological AIDS and death. For a subgroup analysis of cases with 
estimated seroconversion dates, disease progression was adjusted to include a definition from 
seroconversion to immunological AIDS and death. While it would have been preferred, clinical 
AIDS was not chosen as a outcome, as this data was only collected at the PLP site. Due to the 
relatively short follow-up time within the dataset, and other limitations of a CD4 cell decline 
measure (see section 2.3), this outcome was not used.  Opportunistic infections were recorded as 
yes/no for the WCC, and date of opportunisitc infection for the PLP; for this reason, 
opportunistics infections could not be considered an outcome.
There were two outcome variables (i.e. event) as follow:
(1) Time to immunological AIDS(CD4 count <200 cells/µl)  
(2) Time to death
3.9. Statistical analysis 
The data was cleaned by checking the distribution of variables. Potentially incorrect values were 
identified in this process.  
Descriptive statistics were then used to summarize the data. To compare dichotomous variables, 
chi-square or Fishers exact test were used.  For continuous variables, t-test were used.  
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Time-to-event was the statistical method used to analyze HIV disease progression.158 The events 
of interest were immunological AIDS and death. Time to immunological AIDS was defined as 
the length of time (in months) from HIV diagnosis to the first CD4 count to drop below 200 
cells/µl. If the individual did not reach a CD4 count of less than 200 cells/µl, that individual was 
censored at his last CD4 count. Individuals with a CD4 count below 200 cells/µl within one 
month of HIV diagnosis were excluded from this analysis. 
Time to death was defined as the length of time (months) from HIV diagnosis to death. An 
individual who did not have the event of interest was censored at his last clinic visit. 
Censoring is a common practice in survival analysis. While it would be ideal to follow all 
patients until the event of interest occurs, that is not always possible. It is not practical or 
economic to follow-up patients for long periods of time.  Also, there will usually be patients who 
are lost to follow-up for some reason or another.  Therefore, the at-risk time that each patient 
contributes ends when the study ends, they are lost to follow-up, or leave the study. In this study, 
censoring was assumed to be random (non-informative). 
The Kaplan-Meier method159 was used to estimate the survival function of time to 
immunological AIDS and death. The log-rank test was used to compare survival time 
distributions among all variables of interest. Cox proportional hazards model160 was used to 
determine independent predictors of disease progression and death.  The β-coefficients were 
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estimated based on the method of maximum likelihood. Ties were analyzed based on Breslow 
method.161 
Cox proportional hazards regression models were constructed using the following steps:  1) 
Variables were added one at a time and compared to the null –2log likelihood value. Those that 
significantly reduced the –2log likelihood value were considered for step two. A p-value of less 
than 0.25 also assisted in the identification of potentially important covariates. 2) Variables 
identified from step one were added together into the model.  Those variables not significant 
were discarded and the –2log likelihood values were compared. 3) Variables previously excluded 
were again added to see if they became significant in the presence of other variables. The aim 
was to identify the model with the smallest –2 log likelihood value.  All 2-way interactions were 
also tested. Adding time-dependent variables one at a time tested the proportional hazards 
assumption.
Only fixed covariates were included in the model. The fixed covariates were the baseline 
demographics, exposure categories (i.e. IDU), Hep C coinfection, and treatment use.  Based on 
the literature, potential confounders that were tested included in the multivariate models were 
age, gender, calendar time, and treatment use.  Goodness of fit test based on Cox-Snell and 
Martingale residuals were run to assess the model. 
As a subgroup analysis, a cohort of patients with estimated seroconversion (infection) dates was 
selected and the analysis was rerun. The time (in months) from the last negative HIV serology to 
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the first positive HIV test was calculated for all patients. Those with a time of 12 months or less 
were selected. The estimated time of seroconversion date was calculated as the midpoint between 
the last negative and first positive HIV serology.65 Additional patients with a positive p24 antigen 
test, indicating a recent HIV infection, were also included. Seroconversion dates for these 
individuals was the date of their p24 antigen test, indicative of a recent infection.26, 27
A significance level of 0.05 was used. All data analyses were performed using SAS version 9.2.
In review, the analysis addressed the following objectives. First, it characterized HIV disease 
progression in terms of time to immunological AIDS and time to death. Second, it identified risk 
factors associated with disease progression to AIDS and death. 
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4. Results
4.1. Data manipulations
Viral load was log transformed in order to normalize its distribution. 
4.2. Study population characteristics
Demographics
There was a total of 343 HIV positive patients. One-hundred and eighty-seven patients (55%)
were from the PLP, 84 (25%) patients from the WCC and an additional 72 (21%) attended both 
clinics.  Among these were 177 males (52%). Ethnic data was unknown for 22 cases, but of the 
remaining 322 patients, 230 (72%) were of self-reported Aboriginal descent. These individuals 
represented First Nations (89%) and Metis (11%), and not Inuit. The remaining non-aboriginals 
comprised of 79 (25%) Caucasians, 10 (3%) African and 2 (1%) other ethnicities.  
The mean age of the population was 35 years (SE = 0.6) at diagnosis. Thirteen patients did not 
have recorded HIV risk factors.  A hierarchal composition of the reported risk factors (see 
appendix 3 for details) showed that 252 (76%) of cases were attributed to IDU, followed by 45 
(14%) for HC, 21 (6%) for MSM and 12 (4%) for MSM/IDU.  
Behavioral Characteristics
A total of 272 (81%) reported a history of IDU. Smoking was only recorded at the PLP site; 132 
(75%) were current-smokers, 22 (13%) ex-smokers and 22 (13%) non-smokers (not shown in 
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table).
Social Characteristics
During follow-up, there was a record of social assistance for 109 (32%) of patients. One-hundred 
and two (30%) had a record of incarceration. 
Clinical Characteristics
Nine patients did not have a hepatitis C antibody test. Of the 334 patients with an antibody test, 
hepatitis C antibodies were present in 264 (79%) patients, of which 248 (94%) had an RNA 
confirmatory test (i.e. PCR test). This revealed 27 (11%) of those with HCV antibodies, did not 
have the virus present in the blood, and thus were not actively infected by HCV. In total, we 
found 22% were HCV antibody negative, 9% were HCV antibody positive, but RNA negative, 
and the remaining 70% were HCV antibody and RNA positive. 
Two-hundred and fifty-three (74%) of patients had a CD4 count measure within 6 months of 
diagnosis. Of these, 53 (20%) had a CD4 count of less than 200, 74 (29%) had a CD4 count 
between 200 and 350, and 54 (29%) had a CD4 count between 350 and 500, and 72 (29%) had a 
CD4 count above 500. The mean CD4 count was 382 cells/µl (SE=14). The mean log viral load 
was 4.38 (SE=0.07).
Antiretroviral therapy information was unknown for 53 cases. Of the remaining 290, 167 (58%) 
patients were on HIV treatment at some point following diagnosis. Excluding the 19 cases with 
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no CD4 count measures, 242 (75%) were eligible for treatment based on a CD4 count of less 
than 350 at some point during follow-up.  Of those that were eligible for treatment, 154 (71%) 
were on treatment at some point. All of these results are summarized in Table 4.1.
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Table 4.1. Study population characteristics (N=343)
Characteristics N % Characteristics N %
DEMOGRAPHICS   SOCIAL CHARACTERISTICS   
Gender Record of Social Assistance
   Males 177 51.6    Yes 109 31.8
   Females 166 48.4    No 234 68.2
Ethnicity History of IDU
   Aboriginal 230 71.7    Yes 272 81.0
   Caucasian 79 24.6    No 64 19.0
   Other 12 3.7 CLINICAL CHARACTERISTICS   
   Missing (22) Hepatitis C Antibodies
Age at Diagnosis    Present 264 79.0
   Under 20 15 4.4    Absent 70 21.0
   20-29 108 31.5    Missing (9)
   30-39 108 31.5 Hepatitis C Status
   40-49 80 23.3    HCV antibody negative 70 22.0
   50 or over 32 9.3    HCV antibody positive, RNA negative 27 8.5
Mean Age at Diagnosis (±s.e.) 35.1 0.6    HCV antibody positive, RNA positive 221 69.5
Exposure Categorya    Missing (25)
   MSM 21 6.4 Ever on ART
   MSM/IDU 12 3.6    Yes 167 57.6
   IDU 252 76.4    No 123 42.4
   HC 45 13.6    Missing (53)
   Missing (13) Eligible for ARTb
Year of Diagnosis    Yes 242 74.5
   2005 54 15.7    No 82 25.5
   2006 41 12.0    Missing (19)
   2007 55 16.0 Of those Eligible for ARTb
   2008 74 21.6    On ART 154 71.0
   2009 88 25.7    Not on ART 63 29.0
   2010 31 9.0    Missing (25)
Site CD4 Counts at Diagnosis
   Positive Living Program 187 54.5    <50 14 5.5
   Westside Community Clinic 84 24.5    50-199 39 15.4
   Both 72 21.0    200-349 74 29.3
SOCIAL CHARACTERISTICS      350-499 54 21.3
Record of Incarceration    ≥500 72 28.5
   Yes 102 29.7    Missing (90)
   No 241 70.3 Mean CD4 Count at Diagnosis (±s.e.) 382.1 14.4
Mean Log10VL at Diagnosis (±s.e.) 4.38 0.07
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aMSM, men who have sex with men; IDU, injection drug use; HC, heterosexual contact
bEligible for antiretroviral therapy (ART) based on  CD4 < 350 cells/µl at some point during follow-up
4.2.1. Differences by gender
These patient characteristics were stratified by gender and a few key differences were observed 
for Aboriginal ethnicity, age at diagnosis, year of diagnosis, HIV risk factors, smoking status, 
record of social assistance, HCV co-infection and CD4 count and VL at diagnosis. These 
significant results are summarized in Table 4.2.
Of the 151 females, 130 (80%) were of Aboriginal descent, while among the 170 males, 100 
(59%) were of Aboriginal descent (p<0.001). Females were significantly younger, with a mean 
age of 31(SE=0.7) compared to males who were roughly 7 years older (39; SE=0.8).  A temporal 
trend was also seen with females accounting for a decreasing proportion of the cases from 59% 
in 2005 to 32% in 2010. Among males, 115 (68%) patients were attributed to IDU, 21 (12%) to 
MSM, 21 (12%) to HC, and 12 (7%) to MSM/IDU.  Among females, 137 (85%) were attributed 
to IDU and 124 (15%) to HC.  
Among those at the PLP, differences in smoking status were noted between females and males 
(p=0.06). Among females, 65 (82%) were current smokers, 5 (6%) ex-smokers and 9(11%) were 
non-smokers, compared to 67 (69%) current smokers, 17 (18%) ex-smokers and 13 (13%) non-
smokers among males.   Females were more likely to have a record of social assistance (40%) 
compared to males (25%; p=0.003).
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Females were also more likely to have a positive HCV antibody test (84% vs. 74% for males; 
p=0.024).  Baseline CD4 counts were significantly higher among females than males (425 vs. 
344, p=0.005). The logVL was significantly lower among females than males (4.10 vs. 4.62, 
p<0.001).
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Table 4.2. Study characteristics stratified by gender (n=343)
 Characteristics
Male Female
 p-value
N % N %
Ethnicity
   Aboriginal 100 58.8 130 86.1 <0.0001
   Non-Aboriginal 70 41.2 21 13.9
   Missing (22)
Mean Age at Diagnosis (s.e.) 38.9 0.8 31.1 0.7 0.093
Exposure Categories
    MSM 21 12.4 0 0.0 <0.0001
    MSM/IDU 12 7.1 0 0.0
    IDU 115 68.1 137 85.1
    HC 21 12.4 24 14.9
    Missing (13)
Year of diagnosis
   2005 22 14.4 32 19.3 0.030
   2006 14 7.9 27 16.3
   2007 32 18.1 23 13.9
   2008 39 22.0 35 21.1
   2009 49 27.7 39 23.5
   2010 21 11.9 10 6.0
History of IDU
   Yes 132 76.7 140 85.4 0.044
   No 40 23.3 24 14.6
   Missing (7)
Smoking Status
   Current Smoker 67 69.1 65 82.3 0.063
   Ex-smoker 17 17.5 5 6.3
   Non-smoker 13 13.4 9 11.4
   Missing (167)
Record of Incarceration 
   Yes 56 31.5 46 27.7 0.447
   No 122 68.5 120 72.3
Record of Social Assistance
   Yes 44 24.7 66 39.8 0.003
   No 134 75.3 100 60.2
Hepatitis C Antibodies
   Present 126 74.1 138 84.2 0.024
   Absent 44 25.9 26 15.9
   Missing (9)
Mean CD4 Count at Diagnosis (±s.e.) 343.7 18.7 425.4 21.8 0.005
Mean Log10VL at Diagnosis (±s.e.) 4.62 0.08 4.10 0.11 <0.0001
* MSM, men who have sex with men; IDU, injection drug use; HC, heterosexual contact
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4.2.2. Differences by ethnicity
Ethnicity was known for 321 study patients. Study characteristics were stratified by Aboriginal 
ethnicity with key differences to note on gender, age at diagnosis, HIV risk factors, site of care, 
smoking status, record of social assistance and incarceration and HCV coinfection. These 
stratified results are summarized in Table 4.3.
Among Aboriginals (n=230), females were more prevalent than males (130 57% vs. 44%, 
respectively). Among non-Aboriginals (n=91), males were much more prevalent at 77%. 
Aboriginals were younger at diagnosis (mean age of 33 vs. 41 for non-Aboriginals) and reported 
different risk factors. HIV acquisition was attributed to IDU for 198 (90%) patients, HC for 16 
(7%) patients, MSM/IDU for 5 (2%) patients, and MSM for 1 (1%) patient. In contrast, HIV 
acquisition was attributed to IDU for 36 (40%) patients among non-Aboriginals. An additional 
28 (31%) were likely due to HC, 20 (22%) to MSM, and 6 (7%) to MSM/IDU.  More 
Aboriginals were noted to be seeking care at the WCC (31%) or both sites (23%) than non-
Aboriginals (4% for WCC, 13% for both sites). The remaining 106 (46%) Aboriginals and 75 
(82%) non-Aboriginals were seeking care at the PLP. 
Among those at the PLP, differences in smoking status were noted between these two groups 
(p<0.001). Among Aboriginals, 95 (91%) were current smokers, 6 (6%) were ex-smokers and 4 
(4%) were non-smokers, compared to 34 (51%) current smokers, 15 (22%) ex-smokers and 18 
(27%) non-smokers for non-Aboriginals.  Compared to non-Aboriginals, Aboriginals were more 
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likely to have a record of social assistance (37% vs. 20%; p=0.002) and incarceration (34% vs. 
22%; p=0.031).
Positive hepatitis C antibody tests were more common among Aboriginals than non-Aboriginal 
(90% vs. 48, p<0.001). For Aboriginals, of those with an RNA test (n=190), 12% had a negative 
RNA result. Among non-Aboriginals with an RNA test (n=42), 10% had a negative RNA result 
(results not in table).  
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Table 4.3. Study characteristics stratified by ethnicity (n=321)
 Characteristics
Aboriginal Non-Aboriginal  
N % N % p-value
Gender
Male 100 43.5 70 76.9 <0.0001
Female 130 56.5 21 23.1
Mean Age at Diagnosis (±s.e.) 33.0 0.6 41.4 1.2 <0.0001
Exposure Categories
MSM 1 0.5 20 22.2 <0.0001
MSM/IDU 5 2.3 6 6.7
IDU 198 90.0 36 40.0
HC 16 7.3 28 31.1
Missing (11)
Site 
Positive Living Program 106 46.1 75 82.4 <0.0001
Westside Community Clinic 71 30.9 4 4.4
Both 53 23.0 12 13.2
History of IDU
Yes 209 93.7 42 46.2 <0.0001
No 14 6.3 49 53.9
Missing (7)
Smoking Status
Current Smoker 95 90.5 34 50.8 <0.0001
Ex-smoker 6 5.7 15 22.4
Non-smoker 4 3.8 18 26.9
Missing (149)
Record of Incarceration 
Yes 79 34.4 20 22.0 0.031
No 151 65.7 71 78.0
Record of Social Assistance
Yes 86 37.4 18 19.8 0.002
No 144 62.6 73 80.2
Hepatitis C Antibodies
Present 203 90.2 43 48.3 <0.0001
Absent 22 9.8 46 51.7
Missing (7)
* MSM, men who have sex with men; IDU, injection drug use; HC, heterosexual contact
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4.2.3. Differences by history of IDU
A history of IDU was unknown for 7 patients. When descriptive analysis was stratified by IDU, 
key differences were noted for gender, ethnicity, age at diagnosis, site of care, smoking status, 
record of incarceration and social assistance, and HCV coinfection. These stratified results are 
summarized in Table 4.4.
There were an equal proportion of females and males among IDUs (n=172), but close to a 2:1 
ratio for non-IDUs (n=64). Among IDUs, 209 (83%) were of self-reported Aboriginal descent, 
while among non-IDUs, only 14 (22%) were of Aboriginal descent (p<0.001).  IDUs were 
younger at diagnosis with a mean age of 34 (SE=0.6) compared to 40 (SE=1.6) for non-IDUs 
(p=0.003). While 60 (94%) non-IDUs received care at PLP, only 127 (47%) IDUs did as well
(p=0.001).
Among IDUs that attended the PLP, 108 (87%) patients were recorded as current smokers, 10 
(8%) as ex-smokers and 6 (5%) as non-smokers. This is in contrast to non-IDUs in which 24 
(46%) patients were current smokers, 12 (23%) were ex-smokers and 16 (31%) were non-
smokers. Compared to non-IDUs, IDUs were more likely to have a record of social assistance 
(36% vs. 5%; p<0.001) and incarceration (37% vs. 11%; p<0.001).
HCV coinfection was much more common among IDUs. An antibody positive test was recorded 
for 253 (95%) IDUs and 5 (8%) non-IDUs (p<0.001). For IDUs, of those with a PCR test 
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(n=238), 10% had a negative PCR result. Among non-IDUs with a PCR test (n=4), 75% had a 
negative PCR result (results not in table). 
Table 4.4. Study characteristics stratified by IDU (n=336)
 Characteristics IDU Non-IDU  p-valueN % N %
Gender
Male 132 48.5 40 62.5 0.044
Female 140 51.5 24 37.5
Aboriginal Ethnicity
Aboriginal 209 83.3 14 22.2 <0.0001
Non-Aboriginal 42 16.7 49 77.8
Missing (22)
Mean Age at Diagnosis, s.e. 33.8 0.6 40.0 1.6 <0.0001
Site 
Positive Living Program 127 46.7 60 93.8 <0.0001
Westside Community Clinic 78 28.7 1 1.6
Both 67 24.6 3 4.7
Smoking Status
Current Smoker 108 87.1 24 46.2 <0.0001
Ex-smoker 10 8.1 12 23.1
Non-smoker 6 4.8 16 30.8
Missing (160)
Record of Incarceration 
Yes 97 35.7 3 4.7 <0.0001
No 175 64.3 61 95.3
Record of Social Assistance
Yes 100 36.8 7 10.9 <0.0001
No 172 63.2 57 89.1
Hepatitis C Antibodies
Present 253 95.1 5 8.1 <0.0001
Absent 13 4.9 57 91.9
Missing (8)
4.2.4. Differences by HCV coinfection
Hepatitis C antibody status was unknown for 9 patients. Given the high overlap between IDUs 
and those HCV coinfected, differences among this latter group closely resembles the differences 
between IDUs and non-IDUs. With minor differences in percentages and p-values, differences 
were similarly noted for gender, ethnicity, age at diagnosis, HIV risk factors, site of care, 
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smoking status, record of incarceration and social assistance, and history of IDU. Please refer to 
Table 4.5 for more detailed information.
Table 4.5. Study characteristics stratified by hepatitis C antibody status, present or absent (n=334)
 Characteristics Hepatitis C+ Hepatitis C- p-valueN % N %
Gender
Male 126 47.7 44 62.9 0.024
Female 138 52.3 26 37.1
Aboriginal Ethnicity
Aboriginal 203 82.5 22 32.4 <0.0001
Non-Aboriginal 43 17.5 46 67.7
Missing (20)
Mean Age at Diagnosis (±s.e.) 34.2 0.6 38.0 1.5 0.008
Exposure Categories
MSM 1 0.4 20 29.0 <0.0001
MSM/IDU 9 3.5 3 4.4
IDU 240 93.8 9 13.0
HC 6 2.3 37 52.2
Missing (9)
Site 
Positive Living Program 128 48.5 58 82.9 <0.0001
Westside Community Clinic 67 25.4 10 14.3
Both 69 26.1 2 2.9
History of IDU
Yes 253 98.1 13 18.6
No 5 1.9 57 81.4 <0.0001
Missing (6)
Smoking Status
Current Smoker 106 85.5 26 51.0 <0.0001
Ex-smoker 10 8.1 11 21.6
Non-smoker 8 6.5 14 27.5
Missing (159)
Record of Incarceration 
Yes 95 36.0 7 10.0 <0.0001
No 169 64.0 63 90.0
Record of Social Assistance
Yes 99 37.5 9 12.9 <0.0001
No 165 62.5 61 87.1
* MSM, men who have sex with men; IDU, injection drug use; HC, heterosexual contact
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Correlations
As becomes evident through the descriptive statistics, there was high correlation between various 
variables. A pearson’s correlation highlights this (see Table 4.6). In particular, there was high 
correlation between IDU and HCV (Pearson’s coefficient 0.832, p<0.001). 
Table 4.6. Pearson’s correlation of select variables
Coefficient
p-value
frequency
IDU HCV Aboriginal Gender Site Incarc-eration
Soc. 
Assistance
IDU
 
1 0.832 0.539 -0.110 0.328 0.266 0.218
<.001 <.001 0.044 <.001 <.001 <.001
336 328 314 336 336 336 336
HCV 
 
0.832 1 0.459 -0.123 0.291 0.230 0.214
<.001 <.001 0.024 <.001 <.001 <.001
328 334 314 334 334 334 334
Aboriginal
 
0.539 0.459 1 -0.302 0.261 0.121 0.170
<.001 <.001 <.001 <.001 0.031 0.002
314 314 321 321 321 321 321
Gender
 
-0.110 -0.123 -0.302 1 -0.114 0.043 -0.166
0.044 0.024 <.001 0.035 0.428 0.002
336 334 321 343 343 343 343
Site
 
0.328 0.291 0.261 -0.114 1 0.081 0.028
<.001 <.001 <.001 0.035 0.134 0.609
336 334 321 343 343 343 343
Incarceration
 
0.266 0.230 0.121 0.043 0.081 1 0.090
<.001 <.001 0.031 0.428 0.134 0.095
336 334 321 343 343 343 343
Social 
Assistance
0.218 0.214 0.170 -0.166 0.028 0.090 1
<.001 <.001 0.002 0.002 0.609 0.095
336 334 321 343 343 343 343
In examining the three variables of interest (i.e. Aboriginal ethnicity, IDU, and HCV coinfection) 
we excluded all patients with unknown aboriginal ethnicity, history of IDU and hepatitis C 
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antibody test result. This resulted in 308 study patients. Of these 308 study patients, 44 (14%) 
did not belong to any of these categories. The break down of the remaining 264 patients is 
presented in Figure 4.1. 
Figure 4.1. Illustration of overlap between Aboriginal ethnicity, history of IDU, and HCV coinfection (n=264)
Figure 4.1 represents the overlap between the three variables of interest for this study, and does 
not imply that Aboriginal ethnicity is a risk factor. This high collinearity is what is seen in our 
study, and does not necessarily reflect all aboriginal communities.
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4.3. Primary outcomes
Immunological AIDS
Of the 343 patients, 19 had no CD4 measures taken during follow-up and were thus excluded. An 
additional 45 patients had a CD4 count <200cells/µl within one month of HIV diagnosis and 
were also excluded. Thus, 279 patients were considered for the survival analysis.  Of these, 101 
(36%) dropped below a CD4 count <200cells/µl at some point during follow-up and 178 (64%) 
patients were censored at the date of their last CD4 count serological test.
Death
Out of the 343 patients, 7 had an unknown date of last visit, and were thus not included in the 
survival analysis. Twenty-three (7%) patients died during follow-up. The remaining 313 (93%) 
were censored at their last clinic visit. Cause of death was unknown for 8 (35%) patients, non-
HIV related for 8 (35%) patients and HIV-related for 6 (26%) patients. This study did not have 
access to vital statistics, due to privacy and confidentiality policies. Therefore, this data is only 
representative of the information held within the patients’ medical charts. Given the large 
percentage of patients with unknown cause of death, all cause mortality was the outcome 
assessed. Figure 4.2 summarizes the study patients included in both sets of analysis and the 
outcome of interest for each analysis.
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Figure 4.2. Summary of type of analysis and the frequency of the outcome of interest
4.4. Survival analysis
4.4.1. Time to CD4 count <200cells/µl
The mean and median follow-up time was 1.7 years and 1.3 years, respectively (see Figure 4.3). 
The median time to immunological AIDS was 3.3 years (95%CI: 2.7-5.0 years) from HIV 
diagnosis. There was a 25% probability of progression to immunological AIDS in 1.2 years 
(95%CI: 0.9-1.8 years) and 75% probability in 5.7 years (95%CI: 5.0-5.7 years). 
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Figure 4.3. Survival function of immunological AIDS from HIV diagnosis
Kaplan Meier analysis showed significant differences in survival function for ever recipient of 
ART (log rank test, p=0.001) and year of diagnosis categorized into 2005-2008 and 2009-2010 
(log rank test, p=0.001). Having a record of incarceration was shown to be marginally significant 
(log rank test, p=0.053).  See Figure 4.4. There was no difference among gender, IDU, 
Aboriginal ethnicity, HCV coinfection, and record of social assistance.
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Figure 4.4. Survival distribution functions of immunological AIDS, stratified by (a) treatment status, (b) 
record of incarceration, and (c) HIV diagnosis year 
(a) _____ No ART        (b) _____ No record of incarceration
     _____ ART            _____ Incarceration record
c)  ______ Diagnosis year 2005 to 2008
     ______ Diagnosis year 2009 to 2010
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4.4.1.1. Univariable analysis for immunological AIDS
These results of univariable Cox regression analysis show that year of diagnosis, site of care, and 
ever recipient of ART were significant predictors (Table 4.7). Only 2009 and 2010 were 
statistically significant when compared to 2005, while the remaining years were not. Thus, again, 
the decision was made combine the two periods, 2005-2008 and 2009-2010. Any further mention 
of year of diagnosis will refer to this dichotomous variable. Univariable analysis was rerun for 
Aboriginals, IDUs and HCV co-infected patients, separately. A few key differences were note. 
Sex and age at diagnosis became significant for Aboriginals. Among those HCV coinfected, age 
of diagnosis also became significant. Site of care was not significant for IDUs or HCV 
coinfected patients.
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Table 4.7. Univariable Cox regression analysis for immunological AIDS progression
Covariates HR 95% CI p-value
Gender
Female 1.00
Male 1.30 0.87-1.92 0.191
Ethnicity
Non-Aboriginal 1.00
Aboriginal 1.38 0.87-2.19 0.177
Age at Diagnosis 1.02 1.00-1.04 0.113
Year of Diagnosis
2005 1.00
2006 1.45 0.76-2.81 0.274
2007 1.26 0.62-2.58 0.521
2008 1.72 0.85-3.48 0.132
2009 5.57 2.76-11.25 <0.0001
2010 12.25 4.07-36.86 <0.0001
Year of Diagnosis
2005-2008 1.00
2009-2010 4.35 2.61-7.25 0.000
Site 
Positive Living Program 1.00
Westside Community Clinic 1.83 1.11-3.02 0.019
Both 1.02 0.61-1.70 0.935
IDU Risk Factor
No 1.00
Yes 1.18 0.71-1.97 0.527
History of IDU
Absent 1.00
Present 1.27 0.75-2.15 0.370
Hepatitis C Antibodies
No 1.00
Yes 1.54 0.91-2.60 0.107
Hepatitis C Categories
HCV- 1.00
HCV+, RNA- 0.69 0.40-1.18 0.179
HCV+, RNA+ 1.18 0.62-2.24 0.613
Ever on Antiretroviral therapy
No 1.00
Yes 2.15 1.32-3.51 0.002
Among those eligible for ART
    Not on ART 1.00
    On ART 1.23 0.76-2.00 0.407
Record of Incarceration
    No 1.00
    Yes 1.46 0.98-2.19 0.063
Record of Social Assistance
    No 1.00
    Yes 1.40 0.94-2.07 0.095
CD4 Counts at Diagnosisa 0.92 0.90-0.96 <0.0001
aPer every 10 unit increase in CD4 counts/µl
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4.4.1.2. Multivariable analysis for immunological AIDS
From univariable survival analysis it was determined that sex, ethnicity, age at diagnosis, year of 
diagnosis, site, HCV coinfection, antiretroviral therapy, and record of incarceration and social 
assistance could be potentially important covariate, based on a p-value of less than 0.25. With the 
addition of history of IDU, multivariable model was initiated with these potential covariates. 
Due to the high multi-collinearity between the three groups of interest, three separate models 
were constructed. No effect modifiers or interactions were noted in the creation of any of the 
models.
Model 1: Aboriginal Ethnicity
For this model Aboriginal ethnicity, age, treatment, and year of diagnosis remained as significant 
predictors of time to immunological AIDS. Gender was not found to significantly contribute to 
the model, nor did it significantly alter the other variables and was thus not included in the 
model.  Thus, when controlling for the other variables in the model, the analysis showed an 
elevated risk of developing immunological AIDS was associated with older age (HR, 1.03; 
95%CI, 1.01-1.06, per 1-year increase), ever being on treatment (HR, 2.86; 95%CI 1.72-4.75) 
and an HIV diagnosis in 2009-2010, when compared to 2005-2008 (HR, 5.14; 95%CI, 
2.93-9.00).  Compared to non-Aboriginals, Aboriginal ethnicity was also associated with an 
increased risk of developing immunological AIDS (HR, 1.86; 1.10-3.16).
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Table 4.8. Multivariable Cox regression analysis for Aboriginal ethnicity (Model 1) 
Covariates HRadj 95% CI p-value
Age at Diagnosis 1.03 1.01-1.06 0.005
Ever on ART
   No 1.00
   Yes 2.86 1.72-4.75 <0.0001
Year of Diagnosis
   2005-2008 1.00
   2009-2010 5.14 2.93-9.00 <0.0001
Ethnicity
   Non-Aboriginal 1.00
   Aboriginal 1.86 1.10-3.16 0.021
Model 2: HCV coinfection
When controlling for the other variables in Model 2, the analysis showed an elevated risk of 
developing immunological AIDS was associated with older age (HR, 1.02; 95%CI, 1.00-1.05, 
per 1-year increase), ever being on treatment (HR, 3.09; 95%CI 1.86-5.15) and an HIV diagnosis 
in 2009-2010, when compared to 2005-2008 (HR, 5.66; 95%CI, 3.25-9.4).  Finally, compared to 
mono-infected patients, HCV coinfected patients were also associated with an increased risk of 
developing immunological AIDS (HR, 2.11; 95%CI 1.20-3.70).
Table 4.9. Multivariable Cox regression analysis for HCV coinfection (Model 2)
Covariates HRadj 95% CI p-value
Age at Diagnosis 1.02 1.00-1.05 0.018
Ever on ART
   No 1.00
   Yes 3.09 1.86-5.15 <0.0001
Year of Diagnosis
   2005-2008 1.00
   2009-2010 5.66 3.25-9.84 <0.0001
Hepatitis C Antibodies
   Absent 1.00
   Present 2.11 1.20-3.70 0.010
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Model 3: IDU
When controlling for the other variables in Model 3, the analysis showed an elevated risk of 
developing immunological AIDS was associated with older age (HR, 1.02; 95%CI, 1.00-1.04, 
per 1-year increase), ever being on treatment (HR, 3.32; 95%CI 1.94-5.66) and an HIV diagnosis 
in 2009-2010, when compared to 2005-2008 (HR, 5.76; 95%CI, 3.30-10.06).  Finally, compared 
to non-IDU, IDU were marginally associated with an increased risk of developing 
immunological AIDS (HR, 1.69; 95%CI 0.97-2.93).
Table 4.10. Multivariable Cox regression analysis for injection drug use (Model 3)
Covariates HRadj 95% CI p-value
Age at Diagnosis 1.02 1.00-1.04 0.030
Ever on ART
   No 1.00
   Yes 3.32 1.94-5.66 <0.0001
Year of Diagnosis
   2005-2008 1.00
   2009-2010 5.76 3.30-10.06 <0.0001
History of IDU
   No 1.00
   Yes 1.69 0.97-2.93 0.062
4.4.1.3. Multivariate analysis with baseline CD4 counts
Given the importance of baseline CD4 counts as an indicator of disease progression, all three 
models were adjusted for CD4 counts at or within 6 months of HIV diagnosis, a standard 
practice in seroprevalent cohort studies.162 CD4 counts were calculated as to reflect 10 unit 
increases in CD4 cells/µl.
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For Model 1, neither age at diagnosis and Aboriginal ethnicity remained independent predictors 
of disease progression. Those that remained significant were year of diagnosis, treatment and 
baseline CD4 counts.
Table 4.11. Adjusted multivariable model with baseline CD4 counts (Model 1)
Covariates HRadj 95% CI p-value
Age at Diagnosis 1.01 0.98-1.03 0.452
Ever on ART
   No 1.00
   Yes 4.11 1.21-13.90 0.023
Year of Diagnosis
   2005-2008 1.00
   2009-2010 3.13 1.20-8.21 0.020
Ethnicity
   Non-Aboriginal 1.00
   Aboriginal 1.94 0.83-4.56 0.128
CD4 count at Diagnosis 0.95 0.92-0.98 0.004
For Model 2, HCV coinfection remained a significant predictor of disease progression, along 
with year of diagnosis, ART use, and baseline CD4 counts. Age at diagnosis was not longer 
significant. 
Table 4.12. Adjusted multivariable model with baseline CD4 counts (Model 2)
Covariates HRadj 95% CI p-value
Age at Diagnosis 1.01 0.98-1.03 0.459
Ever on ART
   No 1.00
   Yes 4.89 1.45-16.46 0.010
Year of Diagnosis
   2005-2008 1.00
   2009-2010 3.36 1.26-8.97 0.016
HCV Ab
   No 1.00
   Yes 2.91 1.22-6.95 0.016
CD4 count at Diagnosis 0.95 0.92-0.98 0.0001
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Finally, Model 3 found IDU became a significant as a predictor of disease progression (p=0.02). 
Year of diagnosis, ART use, and baseline CD4 counts were significant predictors in this model. 
Age at diagnosis was not longer significant. 
Table 4.13. Adjusted multivariable model with baseline CD4 counts (Model 3)
Covariates HRadj 95% CI p-value
Age at Diagnosis 1.01 0.98-1.05 0.481
Ever on ART
   No 1.00
   Yes 5.00 1.48-16.92 0.010
Year of Diagnosis
   2005-2008 1.00
   2009-2010 3.08 1.13-8.40 0.016
History of IDU
   No 1.00
   Yes 2.95 1.22-7.13 0.016
CD4 count at Diagnosis 0.95 0.92-0.98 <0.0001
The assumptions of proportional hazards was tested by adding time-dependent covariates with 
the three covariate of interest, Aboriginal ethnicity, HCV coinfection and IDU. The assumption 
of proportional hazards was met in all models. Goodness of fit was tested using Cox-Snell 
residuals. All models were found to have a satisfactory fit.
4.4.2. Time to death
The mean and median follow-up time was 2.0 years and 1.72 years, respectively. The median 
survival time and its standard error could not be determined due to the small number of events 
(93% censored). However, the 3 year and 5 year overall survival probability were 88% (95%CI: 
85
82-93%) and 77% (95%CI: 61-87%), respectively. Figure 4.5 shows the survival distribution 
function. 
Figure 4.5. Survival curve for all-cause mortality from HIV diagnosis
Kaplan Meier graphs showed significant differences in survival function for ever recipient of 
ART (log rank test, p=0.012) and HCV coinfection (log rank test, p=0.035). A history of IDU 
was shown to be marginally significant (log rank test, p=0.056).
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4.4.2.1. Univariable analysis for survival
Univariable Cox regression analysis is summarized in Table 4.14. These results show that ever 
recipient of ART was the only significant predictor of survival.  
Table 4.14. Univariable Cox regression analysis for all cause mortality
Covariates HR 95%CI p-value
Sex
   Female 1.00
   Male 0.99 0.43-2.29 0.989
Ethnicity
   Non-Aboriginal 1.00
   Aboriginal 0.90 0.36-2.24 0.819
Age at Diagnosis 1.03 0.99-1.07 0.162
Year of Diagnosis
   2005-2008 1.00
   2009-2010 3.26 0.83-17.80 0.090
Site 
   Positive Living Program 1.00
   Westside Community Clinic 0.68 0.15-3.04 0.618
   Both 0.33 0.08-1.41 0.133
IDU Risk Factor
   No 1.00
   Yes 5.37 0.72-40.09 0.101
History of IDU
   No 1.00
   Yes 5.67 0.76-42.24 0.090
Hepatitis C Antibodies
   Absent 1.00
   Present 6.51 0.88-48.39 0.067
Hepatitis C Categories
   HCV Ab- 1.00
   HCV Ab+, RNA- 0.18 0.02-1.39 0.101
   HCV Ab+, RNA+ 1.73 0.57-5.22 0.334
Ever on Antiretroviral Therapy
   No 1.00
   Yes 0.34 0.14-0.82 0.017
CD4 Counts at Diagnosisa 1.00 0.98-1.03 0.800
aPer every 10 unit increase in CD4 counts/µl
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Univariable analysis was rerun for Aboriginals, IDU and HCV co-infected patients, separately. 
Only minor differences were noted. For Aboriginals, use of antiretroviral was not a significant 
predictor (p=0.425). This was also noted for IDUs (p=0.070).  
4.4.2.2. Multivariable analysis for survival
From univariable survival analysis it was determined that age at diagnosis, year of diagnosis, 
site, HCV coinfection, IDU, and antiretroviral therapy could be potentially important covariate, 
based on a p-value of less than 0.25. With the addition of Aboriginal ethnicity, multivariable 
model was initiated with these potential covariates. Due to the high multi-collinearity between 
the three groups of interest, three separate models were constructed. No effect modifiers or 
interactions were noted in the creation of any of the models.
Model 1: Aboriginal Ethnicity
For this model treatment was the only significant predictors of survival. Ever being on treatment 
was associated with an increased risk of death (HR, 0.273; 95%CI: 0.12, 0.76).  
Table 4.15.  Multivariable Cox regression analysis for ethnicity (model 1)
Covariates HRadj 95% CI P-value
Ever on ART
No 1.00
Yes 0.30 0.12-0.76 0.011
Ethnicity
Non-Aboriginal 1.00
Aboriginal 0.88 0.35-2.21 0.778
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Model 2: HCV coinfection
For this model, treatment was the only significant predictors of survival.  Ever being on 
treatment was associated with an increase risk of death (HR, 0.36; 95%CI: 0.15, 0.88).  
Table 4.16.  Multivariable Cox regression analysis for HCV coinfection (model 2)
Covariates HRadj 95% CI p-value
Ever on ART
No 1.00
Yes 0.36 0.15-0.88 0.026
Hepatitis C Antibodies
Absent 1.00
Present 5.98 0.80-44.87 0.082
Model 3: IDU
For this model treatment, was the only significant predictors of survival.  Ever being on 
treatment was associated with an increase risk of death (HR, 0.40; 95%CI: 0.16, 0.99).  
Table 4.17.  Multivariable Cox regression analysis for IDU (model 3)
Covariates HRadj 95% CI p-value
Ever on ART
No 1.00
Yes 0.40 0.16-0.99 0.049
History of IDU
No 1.00
Yes 5.09 0.68-38.27 0.114
Baseline CD4 counts were also added to the models, but this variable did not significantly 
improve the models and was thus eliminated.  The assumptions of proportional hazards was 
tested by adding time-dependent covariates with the three covariate of interest, Aboriginal 
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ethnicity, HCV coinfection and IDU. The assumption of proportional hazards was met in all 
models. Goodness of fit was tested using Cox-Snell residuals. All models were found to have a 
satisfactory fit. 
4.5. Subgroup analysis (Seroconversion Cohort)
A total of 73 patients had a negative HIV serology within 12 months of their first positive HIV 
test or a positive p24 antigen test indicating a recent HIV infection. The seroconversion interval 
(i.e. the time difference between a first antibody positive and last antibody negative HIV tests) 
was within one calendar month for one patient, 1-3 months for six patients, 3-6 months for 31 
patients, 6-9 months for 20 patients, and 9-12 months for 7 patients, and over 12 months for 2 
patients.  For 277 patients, there was missing date for either the positive or negative tests. An 
additional 6 patients had a positive p24 antigen test.
4.5.1. Study population characteristics
While in most cases, the characteristics of this group does not differ greatly from the larger 
cohort, there are a few important differences. A greater proportion of Aboriginals (81% vs. 71%), 
IDUs (93% vs. 81%) and hepatitis C coinfected patients (92% vs. 79%) were present in this 
cohort, in comparison to the seroprevalent cohort. This seroconversion cohort also contained a 
greater proportion of those with a record of incarceration (41% vs. 30%) and social assistance 
(37% vs 32%).  The characteristics of the 73 patients with a seroconversion date are outline in 
Table 4.18.
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Table 4.18. Study characteristics of seroconversion cohort (n=73)
Characteristics N % Characteristics N %
DEMOGRAPHICS SOCIAL CHARACTERISTICS
Gender Record of Social Assistance
   Male 37 50.7     Yes 27 37.0
   Female 36 49.3     No 46 63.0
Ethnicity History of IDU
Aboriginal 56 81.2     Yes 65 92.9
Non-Aboriginal 13 18.8     No 5 7.1
Missing (4)     Missing (3)
Age at Seroconversion Hepatitis C Antibodies
Under 20 4 5.5     Present 66 91.7
20-29 28 38.4     Absent 6 8.3
30-39 27 37.0     Missing (1)
40-49 12 16.4 Hepatitis C Status
50 or over 2 2.7     HCV Ab negative 6 8.6
Mean Age at Seroconversion,(±s.e.) 34.2 1.0     HCV Ab positive, RNA negative 5 7.1
Exposure Categories     HCV Ab positive, RNA positive 59 84.3
MSM 1 1.4     Missing (3)
MSM/IDU 2 2.8 Ever on Antiretroviral Therapy
IDU 64 88.9     Yes 30 41.1
HC 5 6.9     No 27 37.0
Missing (1)     Missing (16)
Year of Seroconversion Eligible for ART (based on CD4 < 350)
2005 10 13.7     Yes 41 56.2
2006 14 19.2     No 27 37.0
2007 10 13.7     Missing (5)
2008 15 20.6 Of those Eligible for ART
2009 18 24.7     On ART 25 71.4
2010 6 8.2     Not on ART 10 28.6
Site     Missing (6)
Positive Living Program 42 57.5 CD4 Counts at Seroconversion
Westside Community Clinic 11 15.1     <50 3 6.3
Both 20 27.4     50-199 5 10.4
SOCIAL CHARACTERISTICS     200-349 11 22.9
Smoking Status     350-499 10 20.8
Current Smoker 36 85.7     ≥500 19 39.6
Ex-smoker 4 9.5     Missing (25)
Non-smoker 2 4.8 Mean CD4 Count at Seroconversion (±s.e.) 443.7 38.9
Missing (31) Mean Log10VL at Seroconversion, (±s.e.) 4.36 0.15
Record of Incarceration 
    Yes 30 41.1
    No 43 58.9
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For comparison, a similar figure was created to highlight the overlap in the three variables of 
interest (i.e. Aboriginal ethnicity, IDU, and HCV coinfection). Again, we excluded all patients 
with unknown Aboriginal ethnicity, history of IDU or hepatitis C antibody test result. This 
resulted in 65 study patients. Of these 65 study patients, 2 (3.1%) did not belong to any of these 
categories. The break down of the remaining 63 patients is presented in Figure 4.6. 
Figure 4.6. Illustration of overlap between Aboriginal ethnicity, history of IDU, and HCV coinfection for 
seroconversion cohort (n=63)
Figure 4.6 represents the overlap between the three variables of interest for this study, and does 
not imply that Aboriginal ethnicity is a risk factor. This high collinearity is what is seen in our 
study, and does not necessarily reflect all aboriginal communities.
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4.5.2. Primary outcomes
Immunological AIDS
Within this cohort, 5 patients had no CD4 measures during their follow-up and were thus 
excluded. Therefore, out of the remaining 68 patients, 17 (25.0%) had a CD4 count <200 cells/µl 
while the remaining 75% did not. 
CD4 cell counts can temporarily drop below 200 cells/µl during the acute infection, and thus to 
distinguish between a temporary drop and severe immunological damage indicative of AIDS 
those 17 patients were assessed in more detail.  Of those 17 patients, 8 dipped within 6 months of 
the estimated seroconversion date. Of the eight, one patient had only one CD4 count measure 
and distinguishing between a temporary drop or a consistent drop in CD4 counts was not 
possible; this patient was thus excluded. Four patients did not recover to a CD4 count above 200 
for the remainder of their treatment naïve follow-up, which was at least 6 months long, and thus 
the date of the event of interest remained that first drop. The remaining three patients did have a 
recovery of their CD4 counts above 200 cells/µl. Thus, given that two did not have a drop to 200 
cells/µl, they were recorded as not having the event of interest and censored at their last CD4 
count measure. One patient did drop below 200 cells/µl again, and that second drop was recorded 
as the date of the event of interest. Therefore, overall there were 14 who had a CD4 count <200 
cells/µl, while the remaining 53 patients were censored. 
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Death
Out of the 73 patients, no deaths occurred during the follow-up. 
4.5.3. Survival analysis
Time to CD4 count <200cells/µl
The mean and median follow-up time was 1.91 years and 1.56 years, respectively. The median 
time to immunological AIDS was not able to be determined. However, there was a 25% 
probability of progression to immunological AIDS in 3.45 (lower 95%CI: 0.94), Figure 4.7.
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Figure 4.7. Survival curve for immunological AIDS from HIV infection
Kaplan Meier graphs showed no significant differences by gender, IDU, HCV coinfection, 
Aboriginal ethnicity, treatment, year of seroconversion (dichotomous), incarceration, or social 
assistance.
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Given the high proportion of Aboriginal ethnicity, IDU, and HCV coinfections, this cohort is 
inadequate to further study the effects of these three variables. In both univariable and 
multivariable analysis, none of the covariates were significant predictors of time to 
immunological AIDS.
4.6. Summary of survival analysis 
HIV disease progression was measured from HIV diagnosis to immunological AIDS and death 
and from HIV seroconversion to immunological AIDS in a subgroup with estimable dates of 
seroconversion. As no deaths occurred for this subgroup, this outcome was not assessed. Table 
4.19 summarizes the probability of progression at 1, 3 and 5 years post diagnosis and infection. 
Table 4.19. Summary of percentage without immunological AIDS and survival of HIV positive patients 
 Percent AIDS free Percent surviving
 % 95% CI % 95% CI
After HIV Diagnosis
1 year 77.8 72.1, 82.5 97.6 95.0, 98.8
3 years 53.2 44.8, 60.9 88.7 81.8, 93.1
5 years 33.2 19.2, 47.8 77.0 61.2, 87.0
After HIV Seroconversion
1 year 86.2 74.2, 92.9 n/a n/a
3 years 76.2 61.0, 86.0 n/a n/a
5 years n/a n/a n/a n/a
  CI, confidence intervals; n/a, not available
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5. Discussion
5.1. Summary of findings
This study was based on retrospective data from 343 HIV positive patients receiving care at the 
PLP or WCC in Saskatoon, Saskatchewan. It characterized HIV disease progression among this 
study population and identified factors associated with disease progression. This section will 
briefly summarize the findings of this study, compare these findings to the literature, discuss the 
potential implications of these findings, and comment on the strengths and limitations of the 
study.
Characterizing HIV disease progression
Following HIV diagnosis, we found that the 3-year and 5-year immunological AIDS free 
probability was 53% and 33%, respectively. The 3-year and 5-year survival probability were 
89% and 77%, respectively. In efforts to obtain the true rate of progression, unbiased by delay in 
diagnosis, we performed a subgroup analysis with patients who had an estimated seroconversion 
date. Among this seroconversion cohort, we found that 3 years after seroconversion the 
probability of being immunological AIDS free was 76%. No deaths occurred among this 
subgroup.
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Determinants of HIV disease progression
Determinants of disease progression to immunological AIDS among the seroprevalent cohort 
(i.e. from HIV diagnosis) were history of IDU, HCV coinfection, treatment use, and year of 
diagnosis, when controlling for age at diagnosis and baseline CD4 counts. Ethnicity and gender 
were not significant predictors. Since three separate models were built because of the high 
collinearity between variables, we cannot state that HCV coinfection or a history of IDU were 
independent predictors of each other.
With regards to survival, only treatment use was found to be a significant predictor. HCV 
coinfection was marginally significant (p=0.082), while a history of IDU, ethnicity, gender, age 
at diagnosis, and year of diagnosis were not. 
Among the seroconversion cohort (i.e. from estimated seroconversion dates), the high 
representation of patients reporting a history of IDUs, having HCV coinfection, and an 
Aboriginal ethnicity made it difficult to assess these variables in further detail. However, we did 
assess year of diagnosis, year of seroconversion and age at seroconversion and did not find these 
variables to be significant predictors of progression to immunological AIDS. 
5.2. Comparison of findings
Characterizing HIV disease progression
HIV disease progression in our study was similar to that reported among IDUs in the United 
States. This recent analysis in 2009 of 27,572 IDUs from 33 US states similarly found a 49% 
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probability of progression to AIDS (defined as an AIDS defining illness or CD4 count <200) 
within 3 years of HIV diagnosis.58 The probability of survival 3 years after HIV diagnosis was 
86%. Information on treatment was not available.  In contrast, similar analysis among the MSM 
population (i.e. excluding those in the MSM/IDU) found an AIDS-free probability of 71% three 
years after HIV diagnosis. Both of these studies included patients diagnosed during the HAART 
era (i.e. post-1996).
Other US studies have found a lengthier time to immunological AIDS. Diamond et al79 reported 
a median time to immunological AIDS ranging from 4.8 to 6 years from study enrollment in 
2001. Unlike our study, they reported a higher percentage of patients on treatment and IDUs 
accounted for less than 50% of the study population. Baum et al163 followed 133 drug users in 
Miami, Florida for 30 months in 2009. At 2.5 years following study enrollment, they found the 
probability of progression to immunological AIDS ranged from 15 to 25% depending on crack-
cocaine use. However, understanding the significance of these differences is difficult as the 
delays in diagnosis and varying origin points (e.g. study enrollment) were used. Analysis based 
on seroconversion cohorts are better suited for these comparisons.
Time from HIV infection was slightly faster for this study than what other studies have reported. 
Piroth et al130 reported a median time to immunological AIDS of 6 years and 8 months in France. 
Fifty-seven percent of patients were treated with antiretroviral therapy before the endpoint event. 
In a meta-analysis, Zwahlen et al164 reported similar median duration to CD4 <200 cells/µl 
among low and middle-income countries, at 6.1 years. Only 14% of study population, 
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established in the 1990s, had received ART.  In another study based on the pre-HAART era, 
Lepri et al44 found a median time to immunological AIDS of 6 years for women. There was a 
25% probability of progression to immunological AIDS at 4 years for women and 4.5 years for 
men. Most of these studies had a low proportion of IDUs. In comparison, this study found a 25% 
probability of progression at 3.5 years. However, given the availability of HAART during this 
study period (2005-2010), one would have expected to see a slower progression in HIV disease.
Determinants of HIV disease progression
Baseline CD4 cell count was the most important predictor of progression to immunological 
AIDS, a finding consistent with numerous previous reports.30, 79 However, unlike these studies, 
we did not find baseline CD4 counts to be a predictor of survival. This could be due to the short 
follow-up period of this study, which did not allow for these differences to become significant.
While it may seem contradictory, a positive association between treatment and disease 
progression was observed in our study, as in other studies30, 162 and is due to the preferential 
prescription of ART for persons with advanced disease.165 Such situations have been phrased 
“confounding by severity,” in which the decision to treat are dependent on indicators of 
prognosis.166 This study did not attempt to prove the efficacy of treatment. If this was the case, 
the nonrandom allocation of the treatment would need to be accounted for. Thus, conclusions 
regarding the association of ART use and immunological parameters cannot be made.
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Similar to other seroprevalent cohort studies,127, 128 our analysis showed IDU and HCV 
coinfection were associated with faster progression, independent of baseline CD4 counts. Various 
factors could explain the observed differences. For instance, both smoking and alcohol use, 
factors highly prevalent among HIV populations, have also been shown to be associated with 
HIV progression.95, 113 These factors could not be controlled for in this study. Disparities in 
receipt of, and/or adherence to ART could be another critical confounder.167  On a positive note, 
we found that among those eligible for treatment (CD4 count <350 cells/µl), there were no 
differences in the percentage of patients ever on ART between IDUs and non-IDUs or those 
mono-infected or coinfected with HCV. However, information on when treatment was initiated 
was not available, and therefore we cannot rule out that the prescription of treatment may have 
been delayed for IDUs in comparison to non-IDUs. Adherence information was also not 
available. 
Similar to other studies,46 individuals in this study reported multiple highly correlated risk 
behaviours, making it difficult to distinguish between direct and indirect effects. Due to the high 
collinearity of IDU and HCV coinfection, we could not assess the affect of one of these variables 
independent of the other. Greub et al128 however, have found that HCV seropositive individuals 
and active intravenous drug use were independent predictors in a large Swiss prospective cohort. 
It is possible that either one, both of these factors, or confounders, are negatively affecting 
disease progression in our study population. 
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Calendar time has been shown to be an important predictor of disease progression, but this is 
generally due to differences in treatment across time. The importance of year of diagnosis 
(2005-2008 vs. 2009-2010) was not clearly understood. It was noted that baseline CD4 counts 
were significantly lower among those diagnosed in the last two years, than those diagnosed from 
2005 to 2008. However, when controlling for baseline CD4 counts year of diagnosis remained a 
significant predictor. Nevertheless, in the seroconversion cohort, this variable was not 
significant, suggesting that this variable is not a true predictor of disease progression. This 
finding may suggest an increased delay in diagnosis of HIV in the later years (2009-2010) as the 
epidemic has unfolded resulting in late diagnosis and consequently a faster progression to AIDS. 
Mutlivariable analysis of both the seroprevalent and seroconversion cohorts indicated gender 
was not a significant predictor in our study, a finding consistent with a review of seroconversion 
cohorts in 2005.70 However, similarly to the articles included in the review, significant 
differences were noted in CD4 counts and VL at diagnosis between females and males; females 
had a mean CD4 count of 80 cells/µl higher, and mean log10VL of 0.50 higher than males. These 
findings may point to an earlier diagnosis among females, as they are more likely to be routinely 
screened for HIV as part of prenatal care. Other research, however, has shown that after 
seroconversion VL is lower among women than men.69 One would thus expect these differences 
to translate to differences in disease progression, but despite this the rate of progression has been 
shown to be the same. This observation is not clearly understood, but could relate to biological 
differences. 69, 70
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5.3. Study limitations
There were several limitations to our study. First, this was a retrospective cohort, limiting the 
availability and quality of data collected. There were additional variables, such as treatment 
adherence or alcohol use, that would have been beneficial to capture. As described in the 
conceptual framework, many micro and macro-level factors are influencing disease progression. 
However, data was unavailable, poorly recorded, or recorded inconsistently preventing the 
assessment of these variables, limiting the factors which could be examined in this study. The 
inability to gather all important factors and to gather the data through validated measures 
prevented the discernment between direct and indirect effects, a further limitation of this study. 
Moreover, all exposure categories were self-reported, limiting the accuracy and completeness of 
the data potentially leading to information bias, such as misclassification. Given the use of the 
exposure category hierarchy, that any individual reporting at least one instant of IDU was 
differentially misclassified as belonging to that group. This differential misclassification could 
have masked the effect of IDU on HIV disease progression. 
In addition, this study only included HIV positive individuals who attended clinics.  This has 
likely biased towards a more stable study population and could have potentially biased against 
rapid progressors. For instance, seroconverters who progressed rapidly and died may have been 
less likely to attend clinics, and thus not be represented in this study. A review of community 
hospitalization data in Saskatoon for HIV patients from 2008-2009 indicated a 28% mortality 
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among this population when followed to May 1, 2010.168 Among patients in our study, the 
mortality rate was 6.5%.  Moreover, rapid progressors may have been excluded from the first 
analysis, time from HIV diagnosis to immunological AIDS, as they were more likely to be 
diagnosed with a CD4 count below 200 cells/µl. In short, the findings of this study may not be 
generalizable to all HIV patients in Saskatoon, but rather only to patients in care.
We attempted to reduce problems related to possible low reliability of the case definition (i.e. 
event) by including different outcomes/endpoints. Initially, clinical AIDS was one of these 
outcomes. However, since clinical AIDS was not collected at the WCC, we were unable to use 
time to clinical AIDS as the third outcome. This is a further limitation, as many other studies do 
use this important measure of disease progression. 
The seroconversion cohort introduced further limitations. Only a small proportion (25%) of HIV-
infected individuals had a previous documented negative antibody test. Those who did have a 
documented negative HIV test tended to be IDUs, which brings into question the 
representativeness of this seroconversion. For example, heterosexuals acquiring the virus through 
sexual contact are perceived to be of lower risk, and are therefore less likely to have had a 
previous HIV test. This is a common issue for many seroconversion cohorts.26 We attempted to 
reduce this problem by not selecting too narrow a window period, which would inevitably result 
in the selection of a group of individuals undergoing frequent HIV testing. In addition, when 
reviewing all cases that dropped below a CD4 count of 200 cells/µl, those which had a single 
CD4 count where excluded from the analysis, as we could not conclude if this was a temporary 
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dip in CD4 counts or immunological AIDS. This exclusion may have biased results towards 
slower disease progression.
5.4. Study strengths
This project also had some important strengths, including the serocoversion cohort, the unique 
study population, and the assessment of some under-studied factors. There is high variability in 
the time from HIV infection to diagnosis. The use of diagnosis time as a proxy may introduce a 
substantial amount of noise, resulting in the attenuation of coefficients towards the null. If the 
time to diagnosis depends on factors, such as sex or socioeconomic status, there is also the 
potential for systemic bias.  The subgroup analysis of the seroconversion cohort was able to 
provide a true measure of disease progression, a major strength of this study.  
Furthermore, this study is based on an important and unique population in which little research 
has been done. The province of Saskatchewan has the highest incidence rate of HIV in the 
country and its population sharply contrasts from the national statistics, with an 
overrepresentation of females, Aboriginals and IDUs. Any research that further helps to 
understand the present situation is vital to assisting in the prevention and control of the HIV 
epidemic. 
Moreover, while other studies have examined many potential determinants of disease 
progression, minimal research has assessed ethnicity, and much less Aboriginal ethnicity. The 
Aboriginal people are a particularly vulnerable population in Canada, and assessing ethnicity 
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aids in the acquisition of knowledge of disparities in health among ethnic groups. Our study 
highlighted that HIV positive Aboriginals were particularly burdened by IDU and hepatitis C 
coinfections.  A higher percentage of smoking, incarceration and social assistance were also 
noted among Aboriginal people compared to non-Aboriginals. Fortunately, when controlling for 
other important factors, particularly CD4 counts at diagnosis, ethnicity did not appear to be a 
predictor of disease progression within our follow-up period.  Nevertheless, these other 
differences are important determinants of health, and need to be addressed. 
Finally, our study was further strengthened by the large study population.  This strength is not 
only seen in numbers, but also in the overall representation of the HIV-infected population. 
Between the years of 2005 and 2008, Saskatchewan diagnosed 481 cases. Our study sample 
contained 224 patients diagnosed within that same period, which corresponds to a representation 
of 47% of all HIV diagnoses for the province. While the results of this study cannot be 
generalized to the entire province, it does represent much of the HIV positive population in and 
around Saskatoon.
5.5. Study implications
The rate of HIV disease progression is concerning for this study population. From diagnosis, this 
cohort progressed to AIDS and death at similar rates to IDUs in the United States, a country 
without universal health care. From seroconversion, the population progressed at rates similar or 
slightly faster to those in the pre-HAART era. Many issues appear to inflict this population, 
which could explain the faster progression. The vast majority of the population is highly 
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burdened by co-morbidities, addiction, and low socioeconomic status, which can lead to issues of 
access, engagement and retention into care.167 Within our study, at diagnosis (+6 months), 50.2% 
of patients had CD4 counts below 350 cells/µl, which can be seen as an indicator of access to 
care. Moreover, a survey administered among IDUs in Saskatoon found 46% of participants 
reported they did not go to health care centers even when they thought they should; 
discrimination was the most commonly reported reason for not seeking care.21 A review of 
hospitalization data in Saskatoon, SK from 2008-2010 found that among HIV-infected patients 
not newly diagnosed and eligible for treatment (CD4 <350 cells/µl), only 29% were actively on 
HAART,169 further indicating poor access to care, through low treatment initiation.  These issues 
are not only concerning for the individual, but also signifies a large economic burden for the 
province.
Issues of access, engagement and retention into care can also translate into substantial health care 
cost for the province. As mentioned above, in this study, half of the patients were diagnosed at 
CD4 counts below 350 cells/µl, and thus considered eligible for treatment. Twenty percent had 
CD4 counts below 200 cells/µl. In Calgary, Alberta, Krentz et al170 found that the direct costs of 
medical care in the year following HIV diagnosis for late presented (CD4 <200 cells/µl) was 
more than twice as high as those for early presenters (CD4 >200 cells/µl). The mean cost was 
$18,448 for late presenters compared to $8,455 for early presenters. These additional costs were 
attributable to HIV-related hospital care costs (15 times higher for late presenters) and immediate 
initiation of antiretroviral therapy.  The economic impact of early diagnosis is likely to be quite 
substantial for Saskatchewan.
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The rate of progression highlights the need to have targeted interventions for these particularly 
vulnerable populations to slow disease progression. HAART has made great strides in reducing 
HIV-associated morbidity and mortality. 11 Avenues of increasing treatment uptake and 
adherence to treatment need to be further explored and implemented. For instance, direct 
administered therapy has been shown to increase adherence among IDUs.171 Nevertheless, it is 
evident this population faces many obstacles. Many patients are dealing with numerous other 
issues, including homelessness, addiction, and poverty.16, 17 The basic necessities of these 
individuals need also to be address through a collaborative and integrated program for this 
population.  
5.6. Future research directions
More research is required to support these findings and to clearly determine the mechanisms by 
which IDUs and hepatitis C coinfected patients are more vulnerable to disease progression.  
More detailed variables, such as frequency of IDUs, type of drug, hepatitis C treatment, 
treatment adherence, and number of clinic visits, need to be collected and examined, ideally 
through a prospective cohort. These could further inform policy development and program 
planning. 
In addition, it would be of value to reassess these and other variables in a study population with a 
longer follow-up period. While certain variables may have short-term consequences, in efforts to 
identify factors which may only be evident over the long-term, as has been noted in other studies,
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112 a longer follow-up period is required. The longer follow-up period would also allow the 
acquisition of the median time to immunological AIDS among the seroconversion cohort. This 
information is vital to better understanding the true rate of progression among this population; 
this data would allow for the distinction between a rapid progression or a late HIV diagnosis 
among this population.  
Finally, there is also a need to characterize the influence of biological factors shown to effect 
HIV disease progression. These factors, such as genetic susceptibility, viral strain and immune 
response, continue to be the predominant predictors for disease progression.172 The 
seroconversion cohort, identified through this study, is an ideal population in which to study 
these variables, as the population is rather homogenous.   
5.6. Summary
Identification of factors influencing disease progression is vital to effectively care for patients 
and to improve their quality of life.  In this study, we found that IDU, HCV coinfection, and 
baseline CD4 counts were significant predictors of disease progression. This study highlights the 
need for increased testing and early detection, dedicated resources for clinical care and treatment 
access, and for targeted interventions for these particularly vulnerable populations to slow 
disease progression. Moreover, this study calls for continued research on understanding the 
mechanisms by which disparities exist among various populations with regards to HIV disease 
progression. Results could further increase the understanding of other health care inequalities 
among other marginalized populations. 
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7. APPENDICES
Appendix 1. Definition of Terms
Acquired Immunodeficiency Syndrome (AIDS)   A name given to the most advanced stage of 
HIV-1 infection. The diagnostic hallmark of 
AIDS is the development of  opportunistic 
infections secondary to the 
immunosuppression caused by HIV infection
Antiretroviral Therapy (ART) Medications for the treatment of infection by 
retrovirus, primarily HIV 
Gender A multidimensional social construct that is 
culturally based and historically specific, and 
thus constantly changing; Refers to the social 
prescribed and experienced dimensions of 
femaleness or maleness in a society, and is 
manifested at many levels38
Highly Active Antiretroviral Therapy (HAART)  Antiretroviral drug medication for the 
treatment of HIV, typically taken in a 
combination of three to four drugs 
Human Immunodeficiency Virus (HIV) A retrovirus that is the causative agent of AIDS
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HIV Disease progression Refers to the rate of clinical disease 
progression following infection with HIV; 
there are various definitions differing on their 
endpoint
Injection Drug User (IDU) A person who uses an illicit substance drug 
(e.g. heroin, cocaine) that is administered with 
a needle or syringe
Incidence  The number of new events or occurrences, e.g., 
new cases of disease in a defined population, 
within a specific period time
Men who have sex with Men (MSM) Men who report either homosexual or bisexual 
contact; an epidemiological classification for 
HIV transmission
Prevalence  The number of events, e.g, instances of a given 
disease or other condition, in a given 
population at a designated time 
Seroconversion The development of detectable specific 
antibodies to microorganisms in the blood 
serum as a result of infection
134
Sex             A multidimensional biological construct that 
         encompasses anatomy, physiology, genes and 
         hormones, which together affect how we are 
         labelled and treated in the world38
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Appendix 2. Medical Chart Forms
HIV Case Report Form
 
      HIV Case Reporting Form 
Complete and forward a copy to the office of your regional Medical Health Officer.  Mark it "Confidential". 
 
This report is authorized by law.  Under The Public Health Act it is mandatory to report all cases of HIV and AIDS to the Medical Health Officer of the 
regional health authority, following which mandatory information on confirmed cases will be forwarded to the Chief Medical Health Officer. 
 
Part 1 – Patient Information 
RHA Reporting 
 
Check (?) applicable 
? New case report 
? Updated report 
Date of Last Contact with Patient 
(YYYY/MM/DD) 
 ? Unable to contact 
 ? Lost to follow-up 
 ? Deceased     Date:  _____________ 
HSN 
 
Birth Date 
(YYYY/MM/DD) 
 
Sex ? Male 
  ? Female 
  ? Other 
Pregnant ? Unknown 
   ? No 
   ? Yes   Approx ____ weeks 
Patient Name     Last        First          Middle 
 
 
Alias/Other/Maiden Name(s) Last        First 
 
 
Current Street Address 
 
 
Current City/Town/First Nations Community 
 
Current Province 
 
Current Postal Code 
 
Street Address at time of diagnosis 
 
 
City/Town/First Nations Community at diagnosis Province at diagnosis 
 
Postal Code at diagnosis
 
Country of Birth 
 
Arrival Year in Canada 
(YYYY/MM/DD) 
 
Ethnicity (see over for descriptions) 
? White   ? Black Canadian  ? South Asian   ? Mixed ethnicity 
? First Nations  ? Black African  ? Arab/West Asian  ? Other, specify: 
? Métis   ? East Asian   ? Latin-American   _______________ 
 
Part 2 – Risk(s) Associated with the Transmission of HIV 
Injection Risks 
  Yes   No   Unknown 
   ?    ?    ? Injection drug use (current or past history) 
Sexual Risks  (Respond to each item) 
 
  Yes   No   Unknown 
   ?    ?    ? Heterosexual contact 
   ?    ?    ? Sex with a partner of the same gender 
   ?    ?    ? Heterosexual contact of a bisexual male 
   ?    ?    ? Sex trade worker 
   ?    ?    ? Sexual partner is from an HIV endemic region 
   ?    ?    ? Sexual partner of intravenous drug user (IDU) 
   ?    ?    ? Sexual partner of a person with confirmed or 
 suspected HIV/AIDS 
   ?    ?    ? Past history of sexually transmitted infection (STI) 
Other Risks (Respond to each item) 
 
  Yes   No   Unknown 
   ?    ?    ? Received blood/blood components before 1985 
   ?    ?    ? Occupationally exposed to HIV contaminated blood or body fluids 
   ?    ?    ? Other medical exposure (e.g., surgery, dental, oscopy) 
   ?    ?    ? Non medical exposure (e.g., tattoo, aggravated contact with blood) 
   ?    ?    ? From endemic country (see over for list) 
   ?    ?    ? Perinatal transmission 
 
   ?    ?    ? No identified risk (after asking about all risks) 
 
Part 3 – Laboratory/Clinical Findings 
Is this the first HIV test for this person? 
? Yes  ? No ? Unknown 
City, province, country of first positive HIV test, if outside of Saskatchewan 
Reason for current HIV test  (Check (?) all that apply) 
? Immigration/visa requirement      ? Prenatal screening    ? STI screening   ? Contact of an HIV infected person 
? Needle stick injury, blood/body fluid exposure  ? Symptomatic for disease   ? Insurance requirement 
? History of a known risk factor,  specify:  _________________________________  ? Other, specify:______________________________ 
 
Part 4 – Additional information or comments 
Reporting physician’s name (please PRINT): 
 
 
City/town Phone number 
Referred for ongoing care 
? Yes  ? No 
If yes, name of physician (please PRINT): 
 
 
City/town Phone number 
Name of person completing this form (please PRINT) 
 
 
Date report completed  (YYYY/MM/DD) 
 
Phone number 
Revised January, 2011 
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Appendix 2. Medical Chart Forms 
HIV Initial Assessment Form   - 4 pages
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Appendix 2. Medical Chart Forms
HIV/AIDS Case Report - 2 pages
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Appendix 3. Exposure Category (Risk Factor) Hierarchy
Individuals having a new positive HIV test may belong to more than one exposure category. 
These individuals are assigned to the exposure category listed first (or highest) in the following 
hierarchy, in accordance with PHACs surveillance reporting. 
1. MSM: Male who reports having male sex partner(s), this includes men who report 
either homosexual or bisexual contact
2. MSM/IDU: Men who have had sex with men and have injected drugs.
3. IDU: Person who reports current or prior history of injection drug use
4. Blood / blood product recipient: Person who reports receipt of whole blood or 
blood product (e.g., packed red cells, plasma, platelets, cryoprecipitate, pooled 
concentrates of clotting factor).
5. Heterosexual contact: Male who reports having female sex partner(s) only, and 
females who report having male sex partner(s).
6. Occupational exposure: Exposure to HIV contaminated blood or body fluids, or 
concentrated virus in an occupational setting.
7. Perinatal transmission: Transmission of HIV from an HIV‐infected mother to her 
child either in utero, during childbirth, or through breastfeeding.
8. Other: Cases in which the mode of HIV transmission is known but cannot be 
classified into any of the major exposure categories listed here
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9. NIR (No Identified Risk): Where the history of exposure to HIV through any of the 
modes listed is unknown, or there is no reported history. 
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